{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:54:05Z","timestamp":1792220045414,"version":"4.4.0"},"reference-count":275,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ratchadaphisek Somphot Funding for International Research Conference"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40263-025-01223-2","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:55:21Z","timestamp":1758189321000},"page":"1241-1272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sigma-1 Receptor Ligands for CNS Cancer Treatment"],"prefix":"10.1007","volume":"39","author":[{"given":"Anchalee","family":"Prasansuklab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Safrany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirikalaya","family":"Brimson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-8262","authenticated-orcid":false,"given":"James M.","family":"Brimson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"6","key":"1223_CR1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/cmdc.200700008","volume":"2","author":"IR Baxendale","year":"2007","unstructured":"Baxendale IR, Hayward JJ, Ley SV, Tranmer GK. Pharmaceutical strategy and innovation: an academics perspective. ChemMedChem. 2007;2(6):768\u201388. https:\/\/doi.org\/10.1002\/cmdc.200700008.","journal-title":"ChemMedChem"},{"issue":"7607","key":"1223_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N. New tricks for old drugs. Nature. 2016;534(7607):314\u20136. https:\/\/doi.org\/10.1038\/534314a.","journal-title":"Nature"},{"issue":"7","key":"1223_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrd4609","volume":"14","author":"MJ Waring","year":"2015","unstructured":"Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475\u201386. https:\/\/doi.org\/10.1038\/nrd4609.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1223_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14728222.2020.1805435","volume":"24","author":"JM Brimson","year":"2020","unstructured":"Brimson JM, Brimson S, Chomchoei C, Tencomnao T. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets. 2020;24(10):1009\u201328. https:\/\/doi.org\/10.1080\/14728222.2020.1805435.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"1223_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40263-023-01007-6","volume":"37","author":"DS Malar","year":"2023","unstructured":"Malar DS, Thitilertdecha P, Ruckvongacheep KS, Brimson S, Tencomnao T, Brimson JM. Targeting sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders. CNS Drugs. 2023;37(5):399\u2013440. https:\/\/doi.org\/10.1007\/s40263-023-01007-6.","journal-title":"CNS Drugs"},{"issue":"6","key":"1223_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14728222.2021.1952987","volume":"25","author":"JM Brimson","year":"2021","unstructured":"Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, Tencomnao T. Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the sigma-1 receptor and autophagy. Expert Opin Ther Targets. 2021;25(6):435\u201349. https:\/\/doi.org\/10.1080\/14728222.2021.1952987.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"1223_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64260-9","volume":"14","author":"MI Prasanth","year":"2024","unstructured":"Prasanth MI, Wannigama DL, Reiersen AM, Thitilertdecha P, Prasansuklab A, Tencomnao T, et al. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and long-COVID complications. Sci Rep. 2024;14(1):13462. https:\/\/doi.org\/10.1038\/s41598-024-64260-9.","journal-title":"Sci Rep"},{"issue":"12","key":"1223_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/14728222.2022.2166829","volume":"26","author":"C Chomchoei","year":"2022","unstructured":"Chomchoei C, Brimson JM, Brimson S. Repurposing fluoxetine to treat lymphocytic leukemia: apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opin Ther Targets. 2022;26(12):1087\u201397. https:\/\/doi.org\/10.1080\/14728222.2022.2166829.","journal-title":"Expert Opin Ther Targets"},{"key":"1223_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.117032","volume":"73","author":"AN Fallica","year":"2022","unstructured":"Fallica AN, Ciaffaglione V, Modica MN, Pittal\u00e0 V, Salerno L, Amata E, et al. Structure-activity relationships of mixed \u03c3(1)R\/\u03c3(2)R ligands with antiproliferative and anticancer effects. Bioorg Med Chem. 2022;73:117032. https:\/\/doi.org\/10.1016\/j.bmc.2022.117032.","journal-title":"Bioorg Med Chem"},{"key":"1223_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3389\/fphar.2019.01141","volume":"10","author":"HM Oyer","year":"2019","unstructured":"Oyer HM, Sanders CM, Kim FJ. Small-molecule modulators of sigma1 and sigma2\/TMEM97 in the context of cancer: foundational concepts and emerging themes. Front Pharmacol. 2019;10:1141. https:\/\/doi.org\/10.3389\/fphar.2019.01141.","journal-title":"Front Pharmacol"},{"key":"1223_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/genes12020139","author":"I Pontisso","year":"2021","unstructured":"Pontisso I, Combettes L. Role of sigma-1 receptor in calcium modulation: possible involvement in cancer. Genes. 2021. https:\/\/doi.org\/10.3390\/genes12020139.","journal-title":"Genes"},{"issue":"2","key":"1223_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0006-8993(90)91143-5","volume":"527","author":"SB Hellewell","year":"1990","unstructured":"Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 1990;527(2):244\u201353. https:\/\/doi.org\/10.1016\/0006-8993(90)91143-5.","journal-title":"Brain Res"},{"key":"1223_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0165-6147(92)90030-a","volume":"13","author":"R Quirion","year":"1992","unstructured":"Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio J, Rothman RB, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci. 1992;13:85\u20136. https:\/\/doi.org\/10.1016\/0165-6147(92)90030-a.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"1223_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1124\/jpet.103.051292","volume":"306","author":"T Hayashi","year":"2003","unstructured":"Hayashi T, Su T-p. Intracellular dynamics of \u03c3-1 receptors (\u03c31 binding sites) in NG108-15 cells. J Pharmacol Exp Ther. 2003;306(2):726\u201333. https:\/\/doi.org\/10.1124\/jpet.103.051292.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1223_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/jpet.106.108415","volume":"320","author":"G Cormaci","year":"2007","unstructured":"Cormaci G, Mori T, Hayashi T, Su T-p. Protein kinase A activation down-regulates, whereas extracellular signal-regulated kinase activation up-regulates sigma-1 receptors in B-104 cells: implication for neuroplasticity. J Pharmacol Exp Ther. 2007;320(1):202\u201310. https:\/\/doi.org\/10.1124\/jpet.106.108415.","journal-title":"J Pharmacol Exp Ther"},{"issue":"52","key":"1223_CR16","doi-asserted-by":"publisher","first-page":"22468","DOI":"10.1073\/pnas.0909089106","volume":"106","author":"S-y Tsai","year":"2009","unstructured":"Tsai S-y, Hayashi T, Harvey BK, Wang Y, Wu WW, Shen R-f, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1 GTP pathway. Proc Natl Acad Sci U S A. 2009;106(52):22468\u201373. https:\/\/doi.org\/10.1073\/pnas.0909089106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"1223_CR17","doi-asserted-by":"publisher","first-page":"28198","DOI":"10.1074\/jbc.M802099200","volume":"283","author":"Z Wu","year":"2008","unstructured":"Wu Z, Bowen WD. Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation. J Biol Chem. 2008;283(42):28198\u2013215. https:\/\/doi.org\/10.1074\/jbc.M802099200.","journal-title":"J Biol Chem"},{"issue":"3","key":"1223_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/s0896-6273(02)00677-3","volume":"34","author":"E Aydar","year":"2002","unstructured":"Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron. 2002;34(3):399\u2013410. https:\/\/doi.org\/10.1016\/s0896-6273(02)00677-3.","journal-title":"Neuron"},{"key":"1223_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12858-015-0040-y","volume":"16","author":"N Natsvlishvili","year":"2015","unstructured":"Natsvlishvili N, Goguadze N, Zhuravliova E, Mikeladze D. Sigma-1 receptor directly interacts with Rac1-GTPase in the brain mitochondria. BMC Biochem. 2015;16:11. https:\/\/doi.org\/10.1186\/s12858-015-0040-y.","journal-title":"BMC Biochem"},{"key":"1223_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1476-5381.2011.01417.x","volume":"164","author":"JM Brimson","year":"2011","unstructured":"Brimson JM, Brown CA, Safrany ST. Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor. Br J Pharmacol. 2011;164:772\u201380. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01417.x.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"1223_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.tips.2010.08.007","volume":"31","author":"T-p Su","year":"2010","unstructured":"Su T-p, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010;31(12):557\u201366. https:\/\/doi.org\/10.1016\/j.tips.2010.08.007.","journal-title":"Trends Pharmacol Sci"},{"key":"1223_CR22","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1017\/S1461145714000029","volume":"17","author":"P S\u00e1nchez-bl\u00e1zquez","year":"2014","unstructured":"S\u00e1nchez-bl\u00e1zquez P, Rodr\u00edguez-mu\u00f1oz M, Herrero-labrador R. The calcium-sensitive sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. Int J Neurosychopharmacol. 2014;17:1943\u201355. https:\/\/doi.org\/10.1017\/S1461145714000029.","journal-title":"Int J Neurosychopharmacol."},{"issue":"1\u20132","key":"1223_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/s0169-328x(01)00249-2","volume":"95","author":"MS Ola","year":"2001","unstructured":"Ola MS, Moore P, El-Sherbeny A, Roon P, Agarwal N, Sarthy VP, et al. Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina. Mol Brain Res. 2001;95(1\u20132):86\u201395. https:\/\/doi.org\/10.1016\/s0169-328x(01)00249-2.","journal-title":"Mol Brain Res"},{"issue":"2","key":"1223_CR24","first-page":"408","volume":"55","author":"BJ Vilner","year":"1995","unstructured":"Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55(2):408\u201313.","journal-title":"Cancer Res"},{"issue":"3","key":"1223_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174694","volume":"12","author":"L Pan","year":"2017","unstructured":"Pan L, Pasternak DA, Xu J, Xu M, Lu Z, Pasternak GW, et al. Isolation and characterization of alternatively spliced variants of the mouse sigma1 receptor gene, Sigmar1. PLoS\u00a0One. 2017;12(3):e0174694. https:\/\/doi.org\/10.1371\/journal.pone.0174694.","journal-title":"PLoS\u00a0One"},{"key":"1223_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nature17391","volume":"532","author":"HR Schmidt","year":"2016","unstructured":"Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human \u03c31 receptor. Nature. 2016;532:527\u201330. https:\/\/doi.org\/10.1038\/nature17391.","journal-title":"Nature"},{"issue":"4","key":"1223_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1124\/mol.107.038307","volume":"72","author":"A Pal","year":"2007","unstructured":"Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, et al. Identification of regions of the \u03c3-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol. 2007;72(4):921\u201333. https:\/\/doi.org\/10.1124\/mol.107.038307.","journal-title":"Mol Pharmacol"},{"issue":"29","key":"1223_CR28","doi-asserted-by":"publisher","first-page":"20333","DOI":"10.1074\/jbc.M113.537993","volume":"289","author":"KA Gromek","year":"2014","unstructured":"Gromek KA, Suchy FP, Meddaugh HR, Wrobel RL, LaPointe LM, Chu UB, et al. The oligomeric states of the purified sigma-1 receptor are stabilized by ligands. J Biol Chem. 2014;289(29):20333\u201344. https:\/\/doi.org\/10.1074\/jbc.M113.537993.","journal-title":"J Biol Chem"},{"issue":"2","key":"1223_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1042\/BJ20141321","volume":"466","author":"AK Mishra","year":"2015","unstructured":"Mishra AK, Mavlyutov T, Singh DR, Biener G, Yang J, Oliver JA, et al. The sigma-1 receptors are present in monomeric and oligomeric forms in living cells in the presence and absence of ligands. Biochem J. 2015;466(2):263\u201371. https:\/\/doi.org\/10.1042\/BJ20141321.","journal-title":"Biochem J"},{"issue":"16","key":"1223_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612980","volume":"24","author":"M Kim","year":"2023","unstructured":"Kim M, Bezprozvanny I. Structure-based modeling of sigma 1 receptor interactions with ligands and cholesterol and implications for its biological function. Int J Mol Sci. 2023;24(16):12980. https:\/\/doi.org\/10.3390\/ijms241612980.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1223_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.febslet.2015.01.033","volume":"589","author":"JL Ortega-Roldan","year":"2015","unstructured":"Ortega-Roldan JL, Ossa F, Amin NT, Schnell JR. Solution NMR studies reveal the location of the second transmembrane domain of the human sigma-1 receptor. FEBS Lett. 2015;589(5):659\u201365. https:\/\/doi.org\/10.1016\/j.febslet.2015.01.033.","journal-title":"FEBS Lett"},{"issue":"2","key":"1223_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1021\/acs.jcim.9b00649","volume":"60","author":"G Rossino","year":"2020","unstructured":"Rossino G, Orellana I, Caballero J, Schepmann D, W\u00fcnsch B, Rui M, et al. New insights into the opening of the occluded ligand-binding pocket of sigma1 receptor: binding of a novel bivalent RC-33 derivative. J Chem Inf Model. 2020;60(2):756\u201365. https:\/\/doi.org\/10.1021\/acs.jcim.9b00649.","journal-title":"J Chem Inf Model"},{"key":"1223_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65192","volume":"10","author":"V Zhemkov","year":"2021","unstructured":"Zhemkov V, Ditlev JA, Lee W-R, Wilson M, Liou J, Rosen MK, et al. The role of sigma 1 receptor in organization of endoplasmic reticulum signaling microdomains. Elife. 2021;10:e65192. https:\/\/doi.org\/10.7554\/eLife.65192.","journal-title":"Elife"},{"key":"1223_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-319-50174-1_3","volume-title":"Sigma receptors: their role in disease and as therapeutic targets","author":"F Ossa","year":"2017","unstructured":"Ossa F, Schnell JR, Ortega-Roldan JL. A review of the human sigma-1 receptor structure. In: Smith S, Su T-P, editors. Sigma receptors: their role in disease and as therapeutic targets. Cham: Springer; 2017. p. 15\u201329. https:\/\/doi.org\/10.1007\/978-3-319-50174-1_3."},{"issue":"8","key":"1223_CR35","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1021\/jm00034a020","volume":"37","author":"RA Glennon","year":"1994","unstructured":"Glennon RA, Ablordeppey SY, Ismaiel AM, El-Ashmawy MB, Fischer JB, Howie KB. Structural features important for sigma1 receptor binding. J Med Chem. 1994;37(8):1214\u20139. https:\/\/doi.org\/10.1021\/jm00034a020.","journal-title":"J Med Chem"},{"issue":"10","key":"1223_CR36","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2174\/138955705774329519","volume":"5","author":"RA Glennon","year":"2005","unstructured":"Glennon RA. Pharmacophore identification for sigma-1 \u03c31 receptor binding: application of the \u201cdeconstruction-reconstruction-elaboration\u201d approach. Mini Rev Med Chem. 2005;5(10):927\u201340. https:\/\/doi.org\/10.2174\/138955705774329519.","journal-title":"Mini Rev Med Chem"},{"issue":"8","key":"1223_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.6026\/97320630015586","volume":"15","author":"MA Alamri","year":"2019","unstructured":"Alamri MA, Alamri MA. Pharmacophore and docking-based sequential virtual screening for the identification of novel sigma 1 receptor ligands. Bioinformation. 2019;15(8):586\u201395. https:\/\/doi.org\/10.6026\/97320630015586.","journal-title":"Bioinformation"},{"key":"1223_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fphar.2019.00519","volume":"10","author":"R Pascual","year":"2019","unstructured":"Pascual R, Almansa C, Plata-Salam\u00e1n C, Vela JM. A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset. Front Pharmacol. 2019;10:519. https:\/\/doi.org\/10.3389\/fphar.2019.00519.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1223_CR39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1039\/D4MD00722K","volume":"16","author":"MC Lomuscio","year":"2025","unstructured":"Lomuscio MC, Corriero N, Nanna V, Piccinno A, Saviano M, Lanzilotti R, et al. SIGMAP: an explainable artificial intelligence tool for SIGMA-1 receptor affinity prediction. RSC Med Chem. 2025;16(2):835\u201348. https:\/\/doi.org\/10.1039\/D4MD00722K.","journal-title":"RSC Med Chem."},{"issue":"3","key":"1223_CR40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","volume":"131","author":"T Hayashi","year":"2007","unstructured":"Hayashi T, Su T-p. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131(3):596\u2013610. https:\/\/doi.org\/10.1016\/j.cell.2007.08.036.","journal-title":"Cell"},{"issue":"14","key":"1223_CR41","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-03-3180","volume":"64","author":"BA Spruce","year":"2004","unstructured":"Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MVL, O\u2019Neill M, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64(14):4875\u201386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3180.","journal-title":"Cancer Res"},{"issue":"4","key":"1223_CR42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/157015908787386113","volume":"6","author":"EJ Cobos","year":"2008","unstructured":"Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Pozo ED. Pharmacology and therapeutic potential of sigma1 receptor ligands. Curr Neuropharmacol. 2008;6(4):344\u201366. https:\/\/doi.org\/10.2174\/157015908787386113.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"1223_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/17460441.2021.1838483","volume":"16","author":"T Maurice","year":"2020","unstructured":"Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2020;16(4):373\u201389. https:\/\/doi.org\/10.1080\/17460441.2021.1838483.","journal-title":"Expert Opin Drug Discov"},{"key":"1223_CR44","doi-asserted-by":"publisher","first-page":"9251","DOI":"10.1038\/s41598-020-65849-6","volume":"10","author":"JM Brimson","year":"2020","unstructured":"Brimson JM, Akula KK, Abbas H, Ferry DR, Kulkarni SK, Russell ST, et al. Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression. Sci Rep. 2020;10:9251. https:\/\/doi.org\/10.1038\/s41598-020-65849-6.","journal-title":"Sci Rep"},{"issue":"3","key":"1223_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0022-3565(24)39299-7","volume":"293","author":"T Hayashi","year":"2000","unstructured":"Hayashi T, Maurice T, Su T-P. Ca2+ signaling via sigma1-receptors: novel regulatory mechanism affecting intracellular Ca2+ concentration. J Pharmacol Exp Ther. 2000;293(3):788\u201398. https:\/\/doi.org\/10.1016\/S0022-3565(24)39299-7.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1223_CR46","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1124\/jpet.103.053447","volume":"307","author":"FP Monnet","year":"2003","unstructured":"Monnet FP, Morin-Surun M-P, Leger J, Combettes L. Protein kinase C-dependent potentiation of intracellular calcium influx by \u03c31 receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther. 2003;307(2):705\u201312. https:\/\/doi.org\/10.1124\/jpet.103.053447.","journal-title":"J Pharmacol Exp Ther"},{"issue":"21","key":"1223_CR47","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.1016\/j.bmc.2011.09.016","volume":"19","author":"D Rossi","year":"2011","unstructured":"Rossi D, Pedrali A, Urbano M, Gaggeri R, Serra M, Fern\u00e1ndez L, et al. Identification of a potent and selective \u03c31 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Bioorg Med Chem. 2011;19(21):6210\u201324. https:\/\/doi.org\/10.1016\/j.bmc.2011.09.016.","journal-title":"Bioorg Med Chem"},{"key":"1223_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-319-50174-1_11","volume-title":"Sigma receptors: their role in disease and as therapeutic targets","author":"Y Albayrak","year":"2017","unstructured":"Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. In: Smith SB, Su T-P, editors. Sigma receptors: their role in disease and as therapeutic targets. Cham: Springer; 2017. p. 153\u201361. https:\/\/doi.org\/10.1007\/978-3-319-50174-1_11."},{"key":"1223_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00018-023-05023-z","volume":"81","author":"S Couly","year":"2024","unstructured":"Couly S, Yasui Y, Foncham S, Grammatikakis I, Lal A, Shi L, et al. Benzomorphan and non-benzomorphan agonists differentially alter sigma-1 receptor quaternary structure, as does types of cellular stress. Cell Mol Life Sci. 2024;81:14. https:\/\/doi.org\/10.1007\/s00018-023-05023-z.","journal-title":"Cell Mol Life Sci"},{"key":"1223_CR50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fnins.2019.00733","volume":"13","author":"T Hayashi","year":"2019","unstructured":"Hayashi T. The sigma-1 receptor in cellular stress signaling. Front Neurosci. 2019;13:733. https:\/\/doi.org\/10.3389\/fnins.2019.00733.","journal-title":"Front Neurosci"},{"issue":"S3","key":"1223_CR51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/jpet.122.176040","volume":"385","author":"FA Simin","year":"2023","unstructured":"Simin FA, Schober J. Subcellular localization analysis of sigma 1 receptor (S1R) and binding immunoglobulin protein (BiP) for identification of antagonists versus agonists. J Pharmacol Exp Ther. 2023;385(S3):124. https:\/\/doi.org\/10.1124\/jpet.122.176040.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1223_CR52","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1021\/acschemneuro.3c00206","volume":"14","author":"X Morat\u00f3","year":"2023","unstructured":"Morat\u00f3 X, Fern\u00e1ndez-Due\u00f1as V, P\u00e9rez-Villamor P, Valle-Le\u00f3n M, Vela JM, Merlos M, et al. Development of a novel \u03c31 receptor biosensor based on its heterodimerization with binding immunoglobulin protein in living cells. ACS Chem Neurosci. 2023;14(11):2201\u20137. https:\/\/doi.org\/10.1021\/acschemneuro.3c00206.","journal-title":"ACS Chem Neurosci"},{"key":"1223_CR53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fphar.2019.00223","volume":"10","author":"E Vavers","year":"2019","unstructured":"Vavers E, Zvejniece L, Maurice T, Dambrova M. Allosteric modulators of sigma-1 receptor: a review. Front Pharmacol. 2019;10:223. https:\/\/doi.org\/10.3389\/fphar.2019.00223.","journal-title":"Front Pharmacol"},{"key":"1223_CR54","unstructured":"Brimson JM. The pharmacology of the sigma-1 receptor [Doctoral]: University of Bath; 2010. http:\/\/opus.bath.ac.uk\/19712\/."},{"issue":"2","key":"1223_CR55","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12640-018-9883-5","volume":"34","author":"JM Brimson","year":"2018","unstructured":"Brimson JM, Safrany ST, Qassam H, Tencomnao T. Dipentylammonium binds to the sigma-1 receptor and protects against glutamate toxicity, attenuates dopamine toxicity and potentiates neurite outgrowth in various cultured cell lines. Neurotox Res. 2018;34(2):263\u201372. https:\/\/doi.org\/10.1007\/s12640-018-9883-5.","journal-title":"Neurotox Res"},{"issue":"3","key":"1223_CR56","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1124\/jpet.111.190868","volume":"341","author":"T Mori","year":"2012","unstructured":"Mori T, Hayashi T, Su TP. Compromising \u03c3-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-\u03baB\/Bcl-2-dependent mechanism: potential relevance to Parkinson\u2019s disease. J Pharmacol Exp Ther. 2012;341(3):663\u201371. https:\/\/doi.org\/10.1124\/jpet.111.190868.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1223_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.007694","volume":"8","author":"T Mori","year":"2013","unstructured":"Mori T, Hayashi T, Hayashi E, Su T-P. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS\u00a0One. 2013;8(10):e76941. https:\/\/doi.org\/10.1371\/journal.pone.007694.","journal-title":"PLoS\u00a0One"},{"issue":"8","key":"1223_CR58","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/bph.16003","volume":"180","author":"MC Ruiz-Cantero","year":"2023","unstructured":"Ruiz-Cantero MC, Cort\u00e9s-Montero E, Jain A, Montilla-Garc\u00eda \u00c1, Bravo-Caparr\u00f3s I, Shim J, et al. The sigma-1 receptor curtails endogenous opioid analgesia during sensitization of TRPV1 nociceptors. Br J Pharmacol. 2023;180(8):1148\u201367. https:\/\/doi.org\/10.1111\/bph.16003.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1223_CR59","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/schbul\/sbab137","volume":"48","author":"J Chen","year":"2021","unstructured":"Chen J, Li G, Qin P, Chen J, Ye N, Waddington JL, et al. Allosteric modulation of the sigma-1 receptor elicits antipsychotic-like effects. Schizophr Bull. 2021;48(2):474\u201384. https:\/\/doi.org\/10.1093\/schbul\/sbab137.","journal-title":"Schizophr Bull"},{"issue":"S4","key":"1223_CR60","doi-asserted-by":"publisher","first-page":"S561","DOI":"10.33549\/physiolres.934052","volume":"67","author":"T Stracina","year":"2018","unstructured":"Stracina T, Nov\u00e1kov\u00e1 M. Cardiac sigma receptors-an update. Physiol Res. 2018;67(S4):S561\u201376. https:\/\/doi.org\/10.33549\/physiolres.934052.","journal-title":"Physiol Res"},{"issue":"2","key":"1223_CR61","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1124\/jpet.103.051284","volume":"306","author":"T Hayashi","year":"2003","unstructured":"Hayashi T, Su T-P. \u03c3-1 receptors (\u03c31 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther. 2003;306(2):718\u201325. https:\/\/doi.org\/10.1124\/jpet.103.051284.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"1223_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084082","volume":"22","author":"V Zhemkov","year":"2021","unstructured":"Zhemkov V, Geva M, Hayden MR, Bezprozvanny I. Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases. Int J Mol Sci. 2021;22(8):4082. https:\/\/doi.org\/10.3390\/ijms22084082.","journal-title":"Int J Mol Sci"},{"key":"1223_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/25152564211026505","author":"V Zhemkov","year":"2021","unstructured":"Zhemkov V, Liou J, Bezprozvanny I. Sigma 1 receptor, cholesterol and endoplasmic reticulum contact sites. Contact. 2021. https:\/\/doi.org\/10.1177\/25152564211026505.","journal-title":"Contact"},{"issue":"2","key":"1223_CR64","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1124\/jpet.119.262790","volume":"373","author":"WC Hong","year":"2020","unstructured":"Hong WC. Distinct regulation of \u03c31 receptor multimerization by its agonists and antagonists in transfected cells and rat liver membranes. J Pharmacol Exp Ther. 2020;373(2):290\u2013301. https:\/\/doi.org\/10.1124\/jpet.119.262790.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1223_CR65","first-page":"168","volume":"24","author":"J Chang","year":"2010","unstructured":"Chang J, Su K-P. The lipid raft hypothesis: the relation among omega-3 fatty acids, depression and cardiovascular diseases. Taiwan J Psychiatry. 2010;24(3):168\u201380.","journal-title":"Taiwan J Psychiatry"},{"issue":"8","key":"1223_CR66","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.bbalip.2014.12.014","volume":"1851","author":"CP M\u00fcller","year":"2015","unstructured":"M\u00fcller CP, Reichel M, M\u00fchle C, Rhein C, Gulbins E, Kornhuber J. Brain membrane lipids in major depression and anxiety disorders. Biochim Biophys Acta (BBA) Mol Cell Biol Lipids. 2015;1851(8):1052\u201365. https:\/\/doi.org\/10.1016\/j.bbalip.2014.12.014.","journal-title":"Biochim Biophys Acta (BBA) Mol Cell Biol Lipids"},{"issue":"23","key":"1223_CR67","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1158\/0008-5472.CAN-07-1771","volume":"67","author":"CP Palmer","year":"2007","unstructured":"Palmer CP, Mahen R, Schnell E, Djamgoz MBA, Aydar E. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res. 2007;67(23):11166\u201375. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1771.","journal-title":"Cancer Res"},{"key":"1223_CR68","doi-asserted-by":"publisher","first-page":"5729710","DOI":"10.1155\/2019\/5729710","volume":"2019","author":"A Walczak","year":"2019","unstructured":"Walczak A, Gradzik K, Kabzinski J, Przybylowska-Sygut K, Majsterek I. The role of the ER-induced UPR pathway and the efficacy of its inhibitors and inducers in the inhibition of tumor progression. Oxid Med Cell Longev. 2019;2019:5729710. https:\/\/doi.org\/10.1155\/2019\/5729710.","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"1223_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ncb0311-184","volume":"13","author":"I Tabas","year":"2011","unstructured":"Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13(3):184\u201390. https:\/\/doi.org\/10.1038\/ncb0311-184.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1223_CR70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mco2.27","volume":"2","author":"Y Fu","year":"2020","unstructured":"Fu Y, Zou T, Shen X, Nelson PJ, Li J, Wu C, et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm. 2020;2(1):27\u201359. https:\/\/doi.org\/10.1002\/mco2.27.","journal-title":"MedComm"},{"key":"1223_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.622908","volume":"9","author":"R Vona","year":"2021","unstructured":"Vona R, Iessi E, Matarrese P. Role of cholesterol and lipid rafts in cancer signaling: a promising therapeutic opportunity? Front Cell Dev Biol. 2021;9:622908. https:\/\/doi.org\/10.3389\/fcell.2021.622908.","journal-title":"Front Cell Dev Biol"},{"key":"1223_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101951","volume":"88","author":"H Wu","year":"2023","unstructured":"Wu H, Chen W, Chen Z, Li X, Wang M. Novel tumor therapy strategies targeting endoplasmic reticulum-mitochondria signal pathways. Ageing Res Rev. 2023;88:101951. https:\/\/doi.org\/10.1016\/j.arr.2023.101951.","journal-title":"Ageing Res Rev"},{"key":"1223_CR73","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jcpa.2020.10.006","volume":"181","author":"BG Spencer","year":"2020","unstructured":"Spencer BG, Finnie JW. The role of endoplasmic reticulum stress in cell survival and death. J Comp Pathol. 2020;181:86\u201391. https:\/\/doi.org\/10.1016\/j.jcpa.2020.10.006.","journal-title":"J Comp Pathol"},{"issue":"2","key":"1223_CR74","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21(2):71\u201388. https:\/\/doi.org\/10.1038\/s41568-020-00312-2.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1223_CR75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1083\/jcb.201506022","volume":"213","author":"S Srivats","year":"2016","unstructured":"Srivats S, Balasuriya D, Pasche M, Vistal G, Edwardson JM, Taylor CW, et al. Sigma1 receptors inhibit store-operated Ca2+ entry by attenuating coupling of STIM1 to Orai1. J Cell Biol. 2016;213(1):65\u201379. https:\/\/doi.org\/10.1083\/jcb.201506022.","journal-title":"J Cell Biol"},{"issue":"5","key":"1223_CR76","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1167\/iovs.16-19199","volume":"58","author":"DZ Ellis","year":"2017","unstructured":"Ellis DZ, Li L, Park Y, He S, Mueller B, Yorio T. Sigma-1 receptor regulates mitochondrial function in glucose-and oxygen-deprived retinal ganglion cells. Investig Ophthalmol Vis Sci. 2017;58(5):2755\u201364. https:\/\/doi.org\/10.1167\/iovs.16-19199.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"1223_CR77","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.3892\/ol.2018.9448","volume":"16","author":"Y Wu","year":"2018","unstructured":"Wu Y, Bai X, Li X, Zhu C, Wu ZP. Overexpression of sigma-1 receptor in MCF-7 cells enhances proliferation via the classic protein kinase C subtype signaling pathway. Oncol Lett. 2018;16(5):6763\u20139. https:\/\/doi.org\/10.3892\/ol.2018.9448.","journal-title":"Oncol Lett"},{"issue":"2","key":"1223_CR78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2005.11.011","volume":"242","author":"E Aydar","year":"2006","unstructured":"Aydar E, Onganer P, Perrett R, Djamgoz MB, Palmer CP. The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines. Cancer Lett. 2006;242(2):245\u201357. https:\/\/doi.org\/10.1016\/j.canlet.2005.11.011.","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"1223_CR79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.12.055","volume":"499","author":"KA Fitzgerald","year":"2016","unstructured":"Fitzgerald KA, Malhotra M, Gooding M, Sallas F, Evans JC, Darcy R, et al. A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor. Int J Pharm. 2016;499(1\u20132):131\u201345. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.12.055.","journal-title":"Int J Pharm"},{"issue":"1","key":"1223_CR80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jneuroim.2003.10.020","volume":"147","author":"B Gardner","year":"2004","unstructured":"Gardner B, Zhu LX, Roth MD, Tashkin DP, Dubinett SM, Sharma S. Cocaine modulates cytokine and enhances tumor growth through sigma receptors. J Neuroimmunol. 2004;147(1):95\u20138. https:\/\/doi.org\/10.1016\/j.jneuroim.2003.10.020.","journal-title":"J Neuroimmunol"},{"issue":"7","key":"1223_CR81","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.4049\/jimmunol.170.7.3585","volume":"170","author":"LX Zhu","year":"2003","unstructured":"Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin DP, et al. IL-10 mediates sigma1 receptor-dependent suppression of antitumor immunity. J Immunol. 2003;170(7):3585\u201391. https:\/\/doi.org\/10.4049\/jimmunol.170.7.3585.","journal-title":"J Immunol"},{"key":"1223_CR82","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ejmech.2016.08.067","volume":"124","author":"M Rui","year":"2016","unstructured":"Rui M, Rossi D, Marra A, Paolillo M, Schinelli S, Curti D, et al. Synthesis and biological evaluation of new aryl-alkyl (alkenyl)-4-benzylpiperidines, novel sigma receptor (SR) modulators, as potential anticancer-agents. Eur J Med Chem. 2016;124:649\u201365. https:\/\/doi.org\/10.1016\/j.ejmech.2016.08.067.","journal-title":"Eur J Med Chem"},{"issue":"18","key":"1223_CR83","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/0024-3205(90)90360-4","volume":"46","author":"GE Thomas","year":"1990","unstructured":"Thomas GE, Sz\u00fccs M, Mamone JY, Bem WT, Rush MD, Johnson FE, et al. Sigma and opioid receptors in human brain tumors. Life Sci. 1990;46(18):1279\u201386. https:\/\/doi.org\/10.1016\/0024-3205(90)90360-4.","journal-title":"Life Sci"},{"issue":"2","key":"1223_CR84","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41417-022-00552-4","volume":"30","author":"P Borde","year":"2022","unstructured":"Borde P, Cosgrove N, Charmsaz S, Safrany ST, Young L. An investigation of sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer. Cancer Gene Ther. 2022;30(2):368\u201374. https:\/\/doi.org\/10.1038\/s41417-022-00552-4.","journal-title":"Cancer Gene Ther"},{"key":"1223_CR85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-pharmtox-010611-134537","volume":"52","author":"K Inoki","year":"2012","unstructured":"Inoki K, Kim J, Guan K-L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012;52:381\u2013400. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010611-134537.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5\u20136","key":"1223_CR86","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.mam.2006.08.010","volume":"27","author":"M Kadowaki","year":"2006","unstructured":"Kadowaki M, Karim MR, Carpi A, Miotto G. Nutrient control of macroautophagy in mammalian cells. Mol Aspects Med. 2006;27(5\u20136):426\u201343. https:\/\/doi.org\/10.1016\/j.mam.2006.08.010.","journal-title":"Mol Aspects Med"},{"key":"1223_CR87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-59745-157-4_4","volume-title":"Autophagosome and phagosome Methods in molecular biology","author":"I Tanida","year":"2008","unstructured":"Tanida I, Ueno T, Kominami E. LC3 and autophagy. In: Deretic V, editor. Autophagosome and phagosome Methods in molecular biology, vol. 445. New York: Humana Press; 2008. p. 77\u201388. https:\/\/doi.org\/10.1007\/978-1-59745-157-4_4."},{"issue":"1","key":"1223_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Arozena AA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1\u2013222. https:\/\/doi.org\/10.1080\/15548627.2015.1100356.","journal-title":"Autophagy"},{"key":"1223_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.cophys.2023.100631","volume":"32","author":"HG Jasutkar","year":"2023","unstructured":"Jasutkar HG, Yamamoto A. Autophagy at the synapse, an early site of dysfunction in neurodegeneration. Curr Opin Physiol. 2023;32:100631. https:\/\/doi.org\/10.1016\/j.cophys.2023.100631.","journal-title":"Curr Opin Physiol"},{"key":"1223_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1137870","volume":"11","author":"AV Kumar","year":"2023","unstructured":"Kumar AV, Mills J. Non-canonical autophagy in aging and age-related diseases. Front Cell Dev Biol. 2023;11:1137870. https:\/\/doi.org\/10.3389\/fcell.2023.1137870.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1223_CR91","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","volume":"19","author":"I Dikic","year":"2018","unstructured":"Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349\u201364. https:\/\/doi.org\/10.1038\/s41580-018-0003-4.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"13","key":"1223_CR92","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1101\/gad.1565707","volume":"21","author":"V Karantza-Wadsworth","year":"2007","unstructured":"Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007;21(13):1621\u201335. https:\/\/doi.org\/10.1101\/gad.1565707.","journal-title":"Genes Dev"},{"issue":"6762","key":"1223_CR93","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/45257","volume":"402","author":"XH Liang","year":"1999","unstructured":"Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature. 1999;402(6762):672\u20136. https:\/\/doi.org\/10.1038\/45257.","journal-title":"Nature"},{"issue":"10","key":"1223_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101599","volume":"11","author":"M P\u00e9rez-Hern\u00e1ndez","year":"2019","unstructured":"P\u00e9rez-Hern\u00e1ndez M, Arias A, Mart\u00ednez-Garc\u00eda D, P\u00e9rez-Tom\u00e1s R, Quesada R, Soto-Cerrato V. Targeting autophagy for cancer treatment and tumor chemosensitization. Cancers (Basel). 2019;11(10):1599. https:\/\/doi.org\/10.3390\/cancers11101599.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1223_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1006\/geno.1999.5851","volume":"59","author":"VM Aita","year":"1999","unstructured":"Aita VM, Liang XH, Murty V, Pincus DL, Yu W, Cayanis E, et al. Cloning and genomic organization of Beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics. 1999;59(1):59\u201365. https:\/\/doi.org\/10.1006\/geno.1999.5851.","journal-title":"Genomics"},{"issue":"7","key":"1223_CR96","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1056\/NEJMra1205406","volume":"368","author":"AM Choi","year":"2013","unstructured":"Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368(7):651\u201362. https:\/\/doi.org\/10.1056\/NEJMra1205406.","journal-title":"N Engl J Med"},{"issue":"1","key":"1223_CR97","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1172\/jci73941","volume":"125","author":"E White","year":"2015","unstructured":"White E. The role for autophagy in cancer. J Clin Investig. 2015;125(1):42\u20136. https:\/\/doi.org\/10.1172\/jci73941.","journal-title":"J Clin Investig"},{"issue":"8","key":"1223_CR98","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1101\/gad.2016211","volume":"25","author":"A Takamura","year":"2011","unstructured":"Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011;25(8):795\u2013800. https:\/\/doi.org\/10.1101\/gad.2016211.","journal-title":"Genes Dev"},{"issue":"4","key":"1223_CR99","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41418-018-0252-y","volume":"26","author":"D Denton","year":"2019","unstructured":"Denton D, Kumar S. Autophagy-dependent cell death. Cell Death Differ. 2019;26(4):605\u201316. https:\/\/doi.org\/10.1038\/s41418-018-0252-y.","journal-title":"Cell Death Differ"},{"issue":"9","key":"1223_CR100","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/cdd.2017.84","volume":"24","author":"S Arakawa","year":"2017","unstructured":"Arakawa S, Tsujioka M, Yoshida T, Tajima-Sakurai H, Nishida Y, Matsuoka Y, et al. Role of Atg5-dependent cell death in the embryonic development of Bax\/Bak double-knockout mice. Cell Death Differ. 2017;24(9):1598\u2013608. https:\/\/doi.org\/10.1038\/cdd.2017.84.","journal-title":"Cell Death Differ"},{"issue":"7463","key":"1223_CR101","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nature12313","volume":"500","author":"J F\u00fcllgrabe","year":"2013","unstructured":"F\u00fcllgrabe J, Lynch-Day MA, Heldring N, Li W, Struijk RB, Ma Q, et al. The histone H4 lysine 16 acetyltransferase hMOF regulates the outcome of autophagy. Nature. 2013;500(7463):468\u201371. https:\/\/doi.org\/10.1038\/nature12313.","journal-title":"Nature"},{"issue":"7","key":"1223_CR102","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/cdd.2017.80","volume":"24","author":"SK Dasari","year":"2017","unstructured":"Dasari SK, Bialik S, Levin-Zaidman S, Levin-Salomon V, Merrill AH, Futerman AH, et al. Signalome-wide RNAi screen identifies GBA1 as a positive mediator of autophagic cell death. Cell Death Differ. 2017;24(7):1288\u2013302. https:\/\/doi.org\/10.1038\/cdd.2017.80.","journal-title":"Cell Death Differ"},{"issue":"10","key":"1223_CR103","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.4161\/auto.25889","volume":"9","author":"SU Mir","year":"2013","unstructured":"Mir SU, Schwarze SR, Jin L, Zhang J, Friend W, Miriyala S, et al. Progesterone receptor membrane component 1\/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy. Autophagy. 2013;9(10):1566\u201378. https:\/\/doi.org\/10.4161\/auto.25889.","journal-title":"Autophagy"},{"issue":"5","key":"1223_CR104","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14728222.2021.1939681","volume":"25","author":"MI Prasanth","year":"2021","unstructured":"Prasanth MI, Malar DS, Tencomnao T, Brimson JM. The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer\u2019s. Expert Opin Ther Targets. 2021;25(5):401\u201314. https:\/\/doi.org\/10.1080\/14728222.2021.1939681.","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"1223_CR105","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.4103\/1673-5374.391334","volume":"19","author":"C Fujii","year":"2024","unstructured":"Fujii C, Zorumski CF, Izumi Y. Endoplasmic reticulum stress, autophagy, neuroinflammation, and sigma 1 receptors as contributors to depression and its treatment. Neural Regen Res. 2024;19(10):2202\u201311. https:\/\/doi.org\/10.4103\/1673-5374.391334.","journal-title":"Neural Regen Res"},{"issue":"8","key":"1223_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114619","volume":"43","author":"J Knupp","year":"2024","unstructured":"Knupp J, Chen Y-J, Wang E, Arvan P, Tsai B. Sigma-1 receptor recruits LC3 mRNA to ER-associated omegasomes to promote localized LC3 translation enabling functional autophagy. Cell Rep. 2024;43(8):114619. https:\/\/doi.org\/10.1016\/j.celrep.2024.114619.","journal-title":"Cell Rep"},{"issue":"9","key":"1223_CR107","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1080\/15548627.2019.1586248","volume":"15","author":"H Yang","year":"2019","unstructured":"Yang H, Shen H, Li J, Guo L-W. SIGMAR1\/Sigma-1 receptor ablation impairs autophagosome clearance. Autophagy. 2019;15(9):1539\u201357. https:\/\/doi.org\/10.1080\/15548627.2019.1586248.","journal-title":"Autophagy"},{"issue":"9","key":"1223_CR108","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/ncb0910-823","volume":"12","author":"N Mizushima","year":"2010","unstructured":"Mizushima N, Levine B. Autophagy in mammalian development and differentiation. Nat Cell Biol. 2010;12(9):823\u201330. https:\/\/doi.org\/10.1038\/ncb0910-823.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"1223_CR109","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1046\/j.1460-9568.2003.02950.x","volume":"18","author":"F Langa","year":"2003","unstructured":"Langa F, Codony X, Tovar V, Lavado A, Gim\u00e9nez E, Cozar P, et al. Generation and phenotypic analysis of sigma receptor type I (\u03c31) knockout mice. Eur J Neurosci. 2003;18(8):2188\u201396. https:\/\/doi.org\/10.1046\/j.1460-9568.2003.02950.x.","journal-title":"Eur J Neurosci"},{"issue":"2","key":"1223_CR110","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bbr.2008.11.036","volume":"198","author":"V Sabino","year":"2009","unstructured":"Sabino V, Cottone P, Parylak SL, Steardo L, Zorrilla EP. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res. 2009;198(2):472\u20136. https:\/\/doi.org\/10.1016\/j.bbr.2008.11.036.","journal-title":"Behav Brain Res"},{"key":"1223_CR111","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S506593","author":"W Jiang","year":"2025","unstructured":"Jiang W, Zhang J, Zhang Y, Huang Z. Sigma-1 receptor rescues autophagy through AMPK\/mTOR signaling pathway in sepsis-induced acute kidney injury. Int J Gen Med. 2025. https:\/\/doi.org\/10.2147\/IJGM.S506593.","journal-title":"Int J Gen Med"},{"issue":"5","key":"1223_CR112","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1124\/mol.113.087809","volume":"84","author":"JM Schrock","year":"2013","unstructured":"Schrock JM, Spino CM, Longen CG, Stabler SM, Marino JC, Pasternak GW, et al. Sequential cytoprotective responses to sigma1 ligand\u2013induced endoplasmic reticulum stress. Mol Pharmacol. 2013;84(5):751\u201362. https:\/\/doi.org\/10.1124\/mol.113.087809.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"1223_CR113","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bmc.2013.11.033","volume":"22","author":"K Korpis","year":"2014","unstructured":"Korpis K, Weber F, Brune S, W\u00fcnsch B, Bednarski PJ. Involvement of apoptosis and autophagy in the death of RPMI 8226 multiple myeloma cells by two enantiomeric sigma receptor ligands. Bioorg Med Chem. 2014;22(1):221\u201333. https:\/\/doi.org\/10.1016\/j.bmc.2013.11.033.","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"1223_CR114","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3892\/ol.2016.4074","volume":"11","author":"JK Lee","year":"2016","unstructured":"Lee JK, Nam DH, Lee J. Repurposing antipsychotics as glioblastoma therapeutics: potentials and challenges (Review). Oncol Lett. 2016;11(2):1281\u20136. https:\/\/doi.org\/10.3892\/ol.2016.4074.","journal-title":"Oncol Lett"},{"issue":"s2","key":"1223_CR115","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","volume":"15","author":"QT Ostrom","year":"2013","unstructured":"Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010. Neuro Oncol. 2013;15(s2):ii1\u201356. https:\/\/doi.org\/10.1093\/neuonc\/not151.","journal-title":"Neuro Oncol"},{"issue":"10","key":"1223_CR116","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.bmcl.2017.03.030","volume":"27","author":"JM Salvino","year":"2017","unstructured":"Salvino JM, Srikanth YV, Lou R, Oyer HM, Chen N, Kim FJ. Novel small molecule guanidine sigma1 inhibitors for advanced prostate cancer. Bioorg Med Chem Lett. 2017;27(10):2216\u201320. https:\/\/doi.org\/10.1016\/j.bmcl.2017.03.030.","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"1223_CR117","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1167\/iovs.04-1209","volume":"46","author":"L Wang","year":"2005","unstructured":"Wang L, Prescott AR, Spruce BA, Sanderson J, Duncan G. Sigma receptor antagonists inhibit human lens cell growth and induce pigmentation. Investig Ophthalmol Vis Sci. 2005;46(4):1403\u20138. https:\/\/doi.org\/10.1167\/iovs.04-1209.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"25","key":"1223_CR118","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1021\/jm00103a005","volume":"35","author":"AS Kimes","year":"1992","unstructured":"Kimes AS, Wilson AA, Scheffel U, Campbell BG, London ED. Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for.sigma. binding sites. J Med Chem. 1992;35(25):4683\u20139. https:\/\/doi.org\/10.1021\/jm00103a005.","journal-title":"J Med Chem"},{"issue":"2","key":"1223_CR119","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1039\/D0MD00186D","volume":"12","author":"H Agha","year":"2021","unstructured":"Agha H, McCurdy CR. In vitro and in vivo sigma 1 receptor imaging studies in different disease states. RSC Med Chem. 2021;12(2):154\u201377. https:\/\/doi.org\/10.1039\/D0MD00186D.","journal-title":"RSC Med Chem."},{"issue":"2","key":"1223_CR120","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11307-019-01369-8","volume":"22","author":"KK Gangangari","year":"2020","unstructured":"Gangangari KK, V\u00e1radi A, Majumdar S, Larson SM, Pasternak GW, Pillarsetty NK. Imaging Sigma-1 receptor (S1R) expression using iodine-124-labeled 1-(4-iodophenyl)-3-(2-adamantyl)guanidine ([(124)I]IPAG). Mol Imaging Biol. 2020;22(2):358\u201366. https:\/\/doi.org\/10.1007\/s11307-019-01369-8.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"1223_CR121","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3892\/br.2021.1460","volume":"15","author":"L Gao","year":"2021","unstructured":"Gao L, Chen Y. Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). Biomed Rep. 2021;15(4):84. https:\/\/doi.org\/10.3892\/br.2021.1460.","journal-title":"Biomed Rep"},{"key":"1223_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906134","volume":"12","author":"A Razaghi","year":"2022","unstructured":"Razaghi A, Mansouri L, Brodin O, Bj\u00f6rnstedt M, Lundahl J. Soluble PD-L1 expression after intravenous treatment of cancer patients with selenite in phase i clinical trial. Front Oncol. 2022;12:906134. https:\/\/doi.org\/10.3389\/fonc.2022.906134.","journal-title":"Front Oncol"},{"issue":"2","key":"1223_CR123","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1541-7786.Mcr-17-0166","volume":"16","author":"CM Maher","year":"2018","unstructured":"Maher CM, Thomas JD, Haas DA, Longen CG, Oyer HM, Tong JY, et al. Small-molecule sigma1 modulator induces autophagic degradation of PD-L1. Mol Cancer Res. 2018;16(2):243\u201355. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-17-0166.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"1223_CR124","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1158\/0008-5472.Can-16-1055","volume":"77","author":"JD Thomas","year":"2017","unstructured":"Thomas JD, Longen CG, Oyer HM, Chen N, Maher CM, Salvino JM, et al. Sigma1 targeting to suppress aberrant androgen receptor signaling in prostate cancer. Cancer Res. 2017;77(9):2439\u201352. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-1055.","journal-title":"Cancer Res"},{"issue":"1","key":"1223_CR125","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1523\/jneurosci.15-01-00117.1995","volume":"15","author":"BJ Vilner","year":"1995","unstructured":"Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci. 1995;15(1):117\u201334. https:\/\/doi.org\/10.1523\/jneurosci.15-01-00117.1995.","journal-title":"J Neurosci"},{"issue":"3","key":"1223_CR126","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0014-2999(95)00208-3","volume":"280","author":"RR Matsumoto","year":"1995","unstructured":"Matsumoto RR, Bowen WD, Tom MA, Truong DD, De Costa BR. Characterization of two novel \u03c3 receptor ligands: antidystonic effects in rats suggest \u03c3 receptor antagonism. Eur J Pharmacol. 1995;280(3):301\u201310. https:\/\/doi.org\/10.1016\/0014-2999(95)00208-3.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1223_CR127","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1007\/s12011-023-03947-y","volume":"202","author":"B Y\u0131ld\u0131z","year":"2024","unstructured":"Y\u0131ld\u0131z B, Demirel R, Havadar HB, Y\u0131ld\u0131z G, \u00d6zi\u00e7 C, Kamilo\u011flu NN, et al. Blocking SIG1R along with low cadmium exposure display anti-cancer qualities in both MCF7 and MDA-MB-231 cells. Biol Trace Elem Res. 2024;202(8):3588\u2013600. https:\/\/doi.org\/10.1007\/s12011-023-03947-y.","journal-title":"Biol Trace Elem Res"},{"key":"1223_CR128","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/265056","volume":"2015","author":"S Zhu","year":"2015","unstructured":"Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y. Sigma-1 Receptor antagonist BD1047 reduces mechanical allodynia in a rat model of bone cancer pain through the inhibition of spinal NR1 phosphorylation and microglia activation. Mediat Inflamm. 2015;2015:265056. https:\/\/doi.org\/10.1155\/2015\/265056.","journal-title":"Mediat Inflamm"},{"issue":"1","key":"1223_CR129","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1248\/bpb.b13-00690","volume":"37","author":"D-H Roh","year":"2014","unstructured":"Roh D-H, Yoon S-Y. Sigma-1 receptor antagonist, BD1047 reduces nociceptive responses and phosphorylation of p38 MAPK in mice orofacial formalin model. Biol Pharm Bull. 2014;37(1):145\u201351. https:\/\/doi.org\/10.1248\/bpb.b13-00690.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"1223_CR130","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00210-004-0961-2","volume":"370","author":"NA Colabufo","year":"2004","unstructured":"Colabufo NA, Berardi F, Contino M, Niso M, Abate C, Perrone R, et al. Antiproliferative and cytotoxic effects of some\u202f?2 agonists and\u202f?1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2004;370(2):106\u201313. https:\/\/doi.org\/10.1007\/s00210-004-0961-2.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"1223_CR131","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/bf00233243","volume":"351","author":"M Tanaka","year":"1995","unstructured":"Tanaka M, Shirasaki T, Kaku S, Muramatsu M, Otomo S. Characteristics of binding of [3H] NE-100, a novel sigma-receptor ligand, to guinea-pig brain membranes. Naunyn Schmiedebergs Arch Pharmacol. 1995;351(3):244\u201351. https:\/\/doi.org\/10.1007\/bf00233243.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"1223_CR132","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100735","volume":"17","author":"C Holtschulte","year":"2022","unstructured":"Holtschulte C, B\u00f6rgel F, Westph\u00e4linger S, Schepmann D, Civenni G, Laurini E, et al. Synthesis of aminoethyl-substituted piperidine derivatives as \u03c3(1) receptor ligands with antiproliferative properties. ChemMedChem. 2022;17(7):e202100735. https:\/\/doi.org\/10.1002\/cmdc.202100735.","journal-title":"ChemMedChem"},{"issue":"3","key":"1223_CR133","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0969-8051(97)00170-4","volume":"25","author":"K Ishiwata","year":"1998","unstructured":"Ishiwata K, Noguchi J, Ishii S-I, Hatano K, Ito K, Nabeshima T, et al. Synthesis and preliminary evaluation of [11C]NE-100 labeled in two different positions as a PET \u03c3 receptor ligand. Nucl Med Biol. 1998;25(3):195\u2013202. https:\/\/doi.org\/10.1016\/S0969-8051(97)00170-4.","journal-title":"Nucl Med Biol"},{"issue":"1\u20133","key":"1223_CR134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2009.03.003","volume":"609","author":"S Ramachandran","year":"2009","unstructured":"Ramachandran S, Chu UB, Mavlyutov TA, Pal A, Pyne S, Ruoho AE. The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur J Pharmacol. 2009;609(1\u20133):19\u201326. https:\/\/doi.org\/10.1016\/j.ejphar.2009.03.003.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1223_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043103","volume":"24","author":"J Li","year":"2023","unstructured":"Li J, Satyshur KA, Guo L-W, Ruoho AE. Sphingoid bases regulate the sigma-1 receptor\u2014sphingosine and N, N\u2032-dimethylsphingosine are endogenous agonists. Int J Mol Sci. 2023;24(4):3103. https:\/\/doi.org\/10.3390\/ijms24043103.","journal-title":"Int J Mol Sci"},{"key":"1223_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0701079","volume":"121","author":"FF Moebius","year":"1997","unstructured":"Moebius FF, Reiter RJ, Hanner M, Glossmann H. High affinity of sigma 1 -binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C 8 - C 7 isomerase. Br J Pharmacol. 1997;121:1\u20136. https:\/\/doi.org\/10.1038\/sj.bjp.0701079.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1223_CR137","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0960-894x(01)00788-0","volume":"12","author":"DY Maeda","year":"2002","unstructured":"Maeda DY, Williams W, Kim WE, Thatcher LN, Bowen WD, Coop A. N-arylalkylpiperidines as high-affinity sigma-1 and sigma-2 receptor ligands: phenylpropylamines as potential leads for selective sigma-2 agents. Bioorg Med Chem Lett. 2002;12(3):497\u2013500. https:\/\/doi.org\/10.1016\/s0960-894x(01)00788-0.","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"1223_CR138","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc2875","volume":"10","author":"NJ Pyne","year":"2010","unstructured":"Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10(7):489\u2013503. https:\/\/doi.org\/10.1038\/nrc2875.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1223_CR139","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.bbamem.2006.05.011","volume":"1758","author":"A G\u00f3mez-Mu\u00f1oz","year":"2006","unstructured":"G\u00f3mez-Mu\u00f1oz A. Ceramide 1-phosphate\/ceramide, a switch between life and death. Biochimica et Biophysica Acta (BBA). 2006;1758(12):2049\u201356. https:\/\/doi.org\/10.1016\/j.bbamem.2006.05.011.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"3","key":"1223_CR140","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.bbagen.2007.10.008","volume":"1780","author":"AR Todeschini","year":"2008","unstructured":"Todeschini AR, Hakomori S-i. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochimica et Biophysica Acta (BBA). 2008;1780(3):421\u201333. https:\/\/doi.org\/10.1016\/j.bbagen.2007.10.008.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"4","key":"1223_CR141","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMct1101691","volume":"366","author":"D Pelletier","year":"2012","unstructured":"Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366(4):339\u201347. https:\/\/doi.org\/10.1056\/NEJMct1101691.","journal-title":"N Engl J Med"},{"issue":"1","key":"1223_CR142","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","volume":"51","author":"OJ David","year":"2012","unstructured":"David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012;51(1):15\u201328. https:\/\/doi.org\/10.2165\/11596550-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1223_CR143","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","volume":"34","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs. 2020;34(11):1191\u2013200. https:\/\/doi.org\/10.1007\/s40263-020-00771-z.","journal-title":"CNS Drugs"},{"issue":"7","key":"1223_CR144","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-022-00927-z","volume":"36","author":"SL Cohan","year":"2022","unstructured":"Cohan SL, Benedict RH, Cree BA, DeLuca J, Hua LH, Chun J. The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis. CNS Drugs. 2022;36(7):703\u201319. https:\/\/doi.org\/10.1007\/s40263-022-00927-z.","journal-title":"CNS Drugs"},{"issue":"11","key":"1223_CR145","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/s1474-4422(19)30239-x","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009\u201320. https:\/\/doi.org\/10.1016\/s1474-4422(19)30239-x.","journal-title":"Lancet Neurol"},{"issue":"19","key":"1223_CR146","doi-asserted-by":"publisher","first-page":"8211","DOI":"10.1021\/jm3007323","volume":"55","author":"JL D\u00edaz","year":"2012","unstructured":"D\u00edaz JL, Cuberes R, Berrocal J, Contijoch M, Christmann U, Fern\u00e1ndez A, et al. Synthesis and biological evaluation of the 1-arylpyrazole class of \u03c31 receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862). J Med Chem. 2012;55(19):8211\u201324. https:\/\/doi.org\/10.1021\/jm3007323.","journal-title":"J Med Chem"},{"issue":"8","key":"1223_CR147","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1111\/j.1476-5381.2012.01942.x","volume":"166","author":"L Romero","year":"2012","unstructured":"Romero L, Zamanillo D, Nadal X, S\u00e1nchez-Arroyos R, Rivera-Arconada I, Dordal A, et al. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol. 2012;166(8):2289\u2013306. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01942.x.","journal-title":"Br J Pharmacol"},{"issue":"28","key":"1223_CR148","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325\u201348. https:\/\/doi.org\/10.1200\/jco.20.01399.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1223_CR149","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2125.2012.04333.x","volume":"75","author":"M Abadias","year":"2013","unstructured":"Abadias M, Escriche M, Vaqu\u00e9 A, Sust M, Encina G. Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies. Br J Clin Pharmacol. 2013;75(1):103\u201317. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04333.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1223_CR150","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13311-017-0572-5","volume":"15","author":"J Bruna","year":"2018","unstructured":"Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C, et al. Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial. Neurotherapeutics. 2018;15(1):178\u201389. https:\/\/doi.org\/10.1007\/s13311-017-0572-5.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1223_CR151","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpainsymman.2009.11.321","volume":"40","author":"JR Hardy","year":"2010","unstructured":"Hardy JR, O\u2019Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manag. 2010;40(1):111\u20136. https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.11.321.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"1223_CR152","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/bf01788847","volume":"4","author":"T Akechi","year":"1996","unstructured":"Akechi T, Uchitomi Y, Okamura H, Fukue M, Kagaya A, Nishida A, et al. Usage of haloperidol for delirium in cancer patients. Support Care Cancer. 1996;4(5):390\u20132. https:\/\/doi.org\/10.1007\/bf01788847.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1223_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02609-w","volume":"13","author":"C Santa","year":"2023","unstructured":"Santa C, Rodrigues D, Coelho JF, Anjo SI, Mendes VM, Bessa-Neto D, et al. Chronic treatment with D2-antagonist haloperidol leads to inhibitory\/excitatory imbalance in striatal D1-neurons. Transl Psychiatry. 2023;13(1):312. https:\/\/doi.org\/10.1038\/s41398-023-02609-w.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1223_CR154","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1006\/bbrc.1996.0208","volume":"219","author":"PJ Brent","year":"1996","unstructured":"Brent PJ, Pang G, Little G, Dosen PJ, Van Helden DF. The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun. 1996;219(1):219\u201326. https:\/\/doi.org\/10.1006\/bbrc.1996.0208.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"1223_CR155","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.ejca.2009.07.011","volume":"45","author":"V M\u00e9galizzi","year":"2009","unstructured":"M\u00e9galizzi V, Decaestecker C, Debeir O, Spiegl-Kreinecker S, Berger W, Lefranc F, et al. Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines. Eur J Cancer. 2009;45(16):2893\u2013905. https:\/\/doi.org\/10.1016\/j.ejca.2009.07.011.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1223_CR156","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0304-3940(96)12711-7","volume":"211","author":"PJ Brent","year":"1996","unstructured":"Brent PJ, Saunders H, Dunkley PR. Intrasynaptosomal free calcium levels in rat forebrain synaptosomes: modulation by sigma (\u03c3) receptor ligands. Neurosci Lett. 1996;211(2):138\u201342. https:\/\/doi.org\/10.1016\/0304-3940(96)12711-7.","journal-title":"Neurosci Lett"},{"issue":"1\u20133","key":"1223_CR157","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2012.01.030","volume":"682","author":"A Pal","year":"2012","unstructured":"Pal A, Fontanilla D, Gopalakrishnan A, Chae Y-K, Markley JL, Ruoho AE. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol. 2012;682(1\u20133):12\u201320. https:\/\/doi.org\/10.1016\/j.ejphar.2012.01.030.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1223_CR158","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0014-2999(95)00115-2","volume":"278","author":"PJ Brent","year":"1995","unstructured":"Brent PJ, Pang GT. Sigma binding site ligands inhibit cel proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol. 1995;278(2):151\u201360. https:\/\/doi.org\/10.1016\/0014-2999(95)00115-2.","journal-title":"Eur J Pharmacol"},{"key":"1223_CR159","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neuroscience.2012.02.035","volume":"209","author":"J Park","year":"2012","unstructured":"Park J, Chung S, An H, Kim J, Seo J, Kim D, et al. Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons. Neuroscience. 2012;209:64\u201373. https:\/\/doi.org\/10.1016\/j.neuroscience.2012.02.035.","journal-title":"Neuroscience"},{"key":"1223_CR160","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neuroscience.2016.10.058","volume":"340","author":"R Kasahara","year":"2017","unstructured":"Kasahara R, Yamamoto N, Suzuki K, Sobue K. The \u03c31 receptor regulates accumulation of GM1 ganglioside-enriched autophagosomes in astrocytes. Neuroscience. 2017;340:176\u201387. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.10.058.","journal-title":"Neuroscience"},{"issue":"1","key":"1223_CR161","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cellsig.2008.10.005","volume":"21","author":"Z Wei","year":"2009","unstructured":"Wei Z, Qi J, Dai Y, Bowen WD, Mousseau DD. Haloperidol disrupts Akt signalling to reveal a phosphorylation-dependent regulation of pro-apoptotic Bcl-XS function. Cell Signal. 2009;21(1):161\u20138. https:\/\/doi.org\/10.1016\/j.cellsig.2008.10.005.","journal-title":"Cell Signal"},{"issue":"3","key":"1223_CR162","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0014-2999(00)00455-6","volume":"401","author":"A Inoue","year":"2000","unstructured":"Inoue A, Sugita S, Shoji H, Ichimoto H, Hide I, Nakata Y. Repeated haloperidol treatment decreases sigma(1) receptor binding but does not affect its mRNA levels in the guinea pig or rat brain. Eur J Pharmacol. 2000;401(3):307\u201316. https:\/\/doi.org\/10.1016\/s0014-2999(00)00455-6.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1223_CR163","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1471-4159.2007.04533.x","volume":"102","author":"EJ Cobos","year":"2007","unstructured":"Cobos EJ, del Pozo E, Baeyens JM. Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J Neurochem. 2007;102(3):812\u201325. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04533.x.","journal-title":"J Neurochem"},{"issue":"4","key":"1223_CR164","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1017\/S1478951514001059","volume":"13","author":"S Boettger","year":"2015","unstructured":"Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects. Palliat Support Care. 2015;13(4):1079\u201385. https:\/\/doi.org\/10.1017\/S1478951514001059.","journal-title":"Palliat Support Care"},{"issue":"6","key":"1223_CR165","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.2042-7158.1990.tb06588.x","volume":"42","author":"FJ Roman","year":"1990","unstructured":"Roman FJ, Pascaud X, Martin B, Vauche D, Junien JL. JO 1784, a potent and selective ligand for rat and mouse brain \u03c3-sites. J Pharm Pharmacol. 1990;42(6):439\u201340. https:\/\/doi.org\/10.1111\/j.2042-7158.1990.tb06588.x.","journal-title":"J Pharm Pharmacol"},{"issue":"11","key":"1223_CR166","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1021\/jm00011a019","volume":"38","author":"J Perregaard","year":"1995","unstructured":"Perregaard J, Moltzen EK, Meier E, Sanchez C. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(. omega.-aminoalkyl)-1H-indoles. J Med Chem. 1995;38(11):1998\u20132008. https:\/\/doi.org\/10.1021\/jm00011a019.","journal-title":"J Med Chem"},{"issue":"1","key":"1223_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3458.2004.tb00001.x","volume":"10","author":"DL Gilmore","year":"2004","unstructured":"Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. CNS Drug Rev. 2004;10(1):1\u201322. https:\/\/doi.org\/10.1111\/j.1527-3458.2004.tb00001.x.","journal-title":"CNS Drug Rev"},{"issue":"1","key":"1223_CR168","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1186\/1742-2094-10-157","volume":"10","author":"X Sun","year":"2013","unstructured":"Sun X, Ji C, Hu T, Wang Z, Chen G. Tamoxifen as an effective neuroprotectant against early brain injury and learning deficits induced by subarachnoid hemorrhage: possible involvement of inflammatory signaling. J Neuroinflamm. 2013;10(1):920. https:\/\/doi.org\/10.1186\/1742-2094-10-157.","journal-title":"J Neuroinflamm"},{"issue":"2","key":"1223_CR169","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/bf00427460","volume":"84","author":"G Chouinard","year":"1984","unstructured":"Chouinard G, Annable L. An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology. 1984;84(2):282\u20134. https:\/\/doi.org\/10.1007\/bf00427460.","journal-title":"Psychopharmacology"},{"issue":"4","key":"1223_CR170","first-page":"173","volume":"18","author":"J Davidson","year":"1982","unstructured":"Davidson J, Miller R, Wingfield M, Zung W, Dren A. The first clinical study of BW-234U in schizophrenia. Psychopharmacol Bull. 1982;18(4):173\u20136.","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"1223_CR171","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.bbrc.2014.12.029","volume":"456","author":"M Happy","year":"2015","unstructured":"Happy M, Dejoie J, Zajac CK, Cortez B, Chakraborty K, Aderemi J, et al. Sigma 1 receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation. Biochem Biophys Res Commun. 2015;456(2):683\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2014.12.029.","journal-title":"Biochem Biophys Res Commun"},{"key":"1223_CR172","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.phrs.2016.05.031","volume":"113","author":"ST Safrany","year":"2016","unstructured":"Safrany ST, Brimson JM. Are fluoxetine\u2019s effects due to sigma-1 receptor agonism? Pharmacol Res. 2016;113:707\u20138. https:\/\/doi.org\/10.1016\/j.phrs.2016.05.031.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1223_CR173","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/nn.4113","volume":"18","author":"GE Hodes","year":"2015","unstructured":"Hodes GE, Kana V, Menard C, Merad M, Russo SJ. Neuroimmune mechanisms of depression. Nat Neurosci. 2015;18(10):1386\u201393. https:\/\/doi.org\/10.1038\/nn.4113.","journal-title":"Nat Neurosci"},{"issue":"9187","key":"1223_CR174","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/s0140-6736(98)11392-2","volume":"354","author":"M Watson","year":"1999","unstructured":"Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet. 1999;354(9187):1331\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(98)11392-2.","journal-title":"Lancet"},{"issue":"4","key":"1223_CR175","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/(sici)1099-1611(199807\/08)7:4<291::Aid-pon361>3.0.Co;2-u","volume":"7","author":"JC Holland","year":"1998","unstructured":"Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998;7(4):291\u2013300. https:\/\/doi.org\/10.1002\/(sici)1099-1611(199807\/08)7:4%3c291::Aid-pon361%3e3.0.Co;2-u.","journal-title":"Psychooncology"},{"issue":"10","key":"1223_CR176","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1200\/jco.2003.08.025","volume":"21","author":"MJ Fisch","year":"2003","unstructured":"Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21(10):1937\u201343. https:\/\/doi.org\/10.1200\/jco.2003.08.025.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1223_CR177","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3109\/10428190903552112","volume":"51","author":"SM Cloonan","year":"2010","unstructured":"Cloonan SM, Drozgowska A, Fayne D, Williams DC. The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma. 2010;51(3):523\u201339. https:\/\/doi.org\/10.3109\/10428190903552112.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1223_CR178","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1742-7843.2009.00509.x","volume":"106","author":"CS Lee","year":"2010","unstructured":"Lee CS, Kim YJ, Jang ER, Kim W, Myung SC. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-\u03baB. Basic Clin Pharmacol Toxicol. 2010;106(6):446\u201353. https:\/\/doi.org\/10.1111\/j.1742-7843.2009.00509.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"1223_CR179","first-page":"3691","volume":"33","author":"AR Mun","year":"2013","unstructured":"Mun AR, Lee S-J, Kim G-B, Kang H-S, Kim J-S, Kim S-J. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013;33(9):3691\u20137.","journal-title":"Anticancer Res"},{"issue":"1","key":"1223_CR180","doi-asserted-by":"publisher","first-page":"G9","DOI":"10.1152\/ajpgi.00267.2010","volume":"301","author":"S-J Koh","year":"2010","unstructured":"Koh S-J, Kim JM, Kim I-K, Kim N, Jung HC, Song IS, et al. Fluoxetine inhibits NF-\u03baB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol. 2010;301(1):G9\u201319. https:\/\/doi.org\/10.1152\/ajpgi.00267.2010.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1223_CR181","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.phrs.2015.11.021","volume":"109","author":"M Emilia","year":"2016","unstructured":"Emilia M, Rosso D, Laura M, Mar\u00eda A. Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug? Pharmacol Res. 2016;109:101\u20137. https:\/\/doi.org\/10.1016\/j.phrs.2015.11.021.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1223_CR182","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.lfs.2013.01.020","volume":"92","author":"LR Frick","year":"2013","unstructured":"Frick LR, Rapanelli M. Antidepressants: influence on cancer and immunity? Life Sci. 2013;92(10):525\u201332. https:\/\/doi.org\/10.1016\/j.lfs.2013.01.020.","journal-title":"Life Sci"},{"issue":"12","key":"1223_CR183","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.euroneuro.2007.03.010","volume":"17","author":"M Taler","year":"2007","unstructured":"Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M, et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007;17(12):774\u201380. https:\/\/doi.org\/10.1016\/j.euroneuro.2007.03.010.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"1223_CR184","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.25477","volume":"128","author":"SM Cloonan","year":"2011","unstructured":"Cloonan SM, Williams DC. The antidepressants maprotiline and fluoxetine induce type II autophagic cell death in drug-resistant Burkitt\u2019s lymphoma. Int J Cancer. 2011;128(7):1712\u201323. https:\/\/doi.org\/10.1002\/ijc.25477.","journal-title":"Int J Cancer"},{"issue":"2","key":"1223_CR185","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4062\/biomolther.2019.103","volume":"28","author":"WW Po","year":"2020","unstructured":"Po WW, Thein W, Khin PP, Khing TM, Han KWW, Park CH, et al. Fluoxetine simultaneously induces both apoptosis and autophagy in human gastric adenocarcinoma cells. Biomol Ther. 2020;28(2):202\u201310. https:\/\/doi.org\/10.4062\/biomolther.2019.103.","journal-title":"Biomol Ther"},{"issue":"9","key":"1223_CR186","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrd1821","volume":"4","author":"DT Wong","year":"2005","unstructured":"Wong DT, Perry KW, Bymaster FP. The discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov. 2005;4(9):764\u201374. https:\/\/doi.org\/10.1038\/nrd1821.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1223_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2832-3-2","volume":"3","author":"A Rossi","year":"2004","unstructured":"Rossi A, Barraco A, Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry. 2004;3(1):2. https:\/\/doi.org\/10.1186\/1475-2832-3-2.","journal-title":"Ann Gen Hosp Psychiatry"},{"issue":"3","key":"1223_CR188","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387\u2013401. https:\/\/doi.org\/10.3390\/neurolint13030038.","journal-title":"Neurol Int"},{"issue":"2","key":"1223_CR189","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/2045125314561467","volume":"5","author":"G Bostankolu","year":"2015","unstructured":"Bostankolu G, Ayhan Y, Cuhadaroglu F, Yaz\u0131c\u0131 MK. Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report. Ther Adv Psychopharmacol. 2015;5(2):138\u201340. https:\/\/doi.org\/10.1177\/2045125314561467.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"1223_CR190","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/s0002-9343(99)00301-0","volume":"108","author":"HW Cohen","year":"2000","unstructured":"Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108(1):2\u20138. https:\/\/doi.org\/10.1016\/s0002-9343(99)00301-0.","journal-title":"Am J Med"},{"issue":"7314","key":"1223_CR191","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/bmj.323.7314.666","volume":"323","author":"J Hippisley-Cox","year":"2000","unstructured":"Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, et al. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. Br Med J. 2000;323(7314):666\u20139. https:\/\/doi.org\/10.1136\/bmj.323.7314.666.","journal-title":"Br Med J"},{"issue":"9","key":"1223_CR192","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.bcp.2008.01.015","volume":"75","author":"LR Frick","year":"2008","unstructured":"Frick LR, Palumbo ML, Zappia MP, Brocco MA, Cremaschi GA, Genaro AM. Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem Pharmacol. 2008;75(9):1817\u201326. https:\/\/doi.org\/10.1016\/j.bcp.2008.01.015.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1223_CR193","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0304-3940(98)00943-4","volume":"260","author":"K Kato","year":"1999","unstructured":"Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett. 1999;260(1):5\u20138. https:\/\/doi.org\/10.1016\/S0304-3940(98)00943-4.","journal-title":"Neurosci Lett"},{"key":"1223_CR194","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.brainres.2009.05.004","volume":"1279","author":"S Kunitachi","year":"2009","unstructured":"Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res. 2009;1279:189\u201396. https:\/\/doi.org\/10.1016\/j.brainres.2009.05.004.","journal-title":"Brain Res"},{"issue":"2","key":"1223_CR195","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-015-2035-3","volume":"127","author":"DD Correa","year":"2016","unstructured":"Correa DD, Kryza-Lacombe M, Baser RE, Beal K, DeAngelis LM. Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study. J Neurooncol. 2016;127(2):313\u20139. https:\/\/doi.org\/10.1007\/s11060-015-2035-3.","journal-title":"J Neurooncol"},{"issue":"15","key":"1223_CR196","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/jco.2014.58.4508","volume":"33","author":"SR Rapp","year":"2015","unstructured":"Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33(15):1653\u20139. https:\/\/doi.org\/10.1200\/jco.2014.58.4508.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1223_CR197","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.neuropharm.2011.07.013","volume":"61","author":"G Winocur","year":"2011","unstructured":"Winocur G, Binns MA, Tannock I. Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology. 2011;61(8):1222\u20138. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.07.013.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1223_CR198","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11764-015-0463-x","volume":"10","author":"JA Lawrence","year":"2016","unstructured":"Lawrence JA, Griffin L, Balcueva EP, Groteluschen DL, Samuel TA, Lesser GJ, et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv. 2016;10(1):176\u201384. https:\/\/doi.org\/10.1007\/s11764-015-0463-x.","journal-title":"J Cancer Surviv"},{"issue":"6","key":"1223_CR199","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1248\/bpb.33.1054","volume":"33","author":"YS Ki","year":"2010","unstructured":"Ki YS, Park EY, Lee H-W, Oh MS, Cho Y-W, Kwon YKIM, et al. Donepezil, a potent acetylcholinesterase inhibitor, induces caspase-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull. 2010;33(6):1054\u20139. https:\/\/doi.org\/10.1248\/bpb.33.1054.","journal-title":"Biol Pharm Bull"},{"key":"1223_CR200","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.trsl.2020.10.010","volume":"230","author":"T Khuanjing","year":"2021","unstructured":"Khuanjing T, Palee S, Kerdphoo S, Jaiwongkam T, Anomasiri A, Chattipakorn SC, et al. Donepezil attenuated cardiac ischemia\/reperfusion injury through balancing mitochondrial dynamics, mitophagy, and autophagy. Transl Res. 2021;230:82\u201397. https:\/\/doi.org\/10.1016\/j.trsl.2020.10.010.","journal-title":"Transl Res"},{"key":"1223_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2022.114175","volume":"438","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Tsuji M, Nakagawasai O, Katsuyama S, Hong L, Miyagawa K, et al. Donepezil prevents olfactory dysfunction and \u03b1-synuclein aggregation in the olfactory bulb by enhancing autophagy in zinc sulfate-treated mice. Behav Brain Res. 2023;438:114175. https:\/\/doi.org\/10.1016\/j.bbr.2022.114175.","journal-title":"Behav Brain Res"},{"issue":"3","key":"1223_CR202","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s10753-022-01621-4","volume":"45","author":"T Jiang","year":"2022","unstructured":"Jiang T, Zhao D, Zheng Z, Li Z. Sigma-1 receptor alleviates airway inflammation and airway remodeling through AMPK\/CXCR4 signal pathway. Inflammation. 2022;45(3):1298\u2013312. https:\/\/doi.org\/10.1007\/s10753-022-01621-4.","journal-title":"Inflammation"},{"issue":"9","key":"1223_CR203","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.21873\/anticanres.12837","volume":"38","author":"JY Kim","year":"2018","unstructured":"Kim JY, Son JY, Lee B-M, Kim HS, Yoon S. Aging-related repositioned drugs, donepezil and sildenafil citrate, increase apoptosis of anti-mitotic drug-resistant KBV20C cells through different molecular mechanisms. Anticancer Res. 2018;38(9):5149\u201357. https:\/\/doi.org\/10.21873\/anticanres.12837.","journal-title":"Anticancer Res"},{"key":"1223_CR204","unstructured":"Health NIf, Excellence C. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease: National Institute for Health and Clinical Excellence; 2011. https:\/\/www.nice.org.uk\/guidance\/ta217. Accessed 14 May 2025."},{"issue":"18","key":"1223_CR205","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","volume":"25","author":"M Geva","year":"2016","unstructured":"Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet. 2016;25(18):3975\u201387. https:\/\/doi.org\/10.1093\/hmg\/ddw238.","journal-title":"Hum Mol Genet"},{"key":"1223_CR206","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00862","volume":"13","author":"DA Ryskamp","year":"2019","unstructured":"Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I. Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci. 2019;13:862. https:\/\/doi.org\/10.3389\/fnins.2019.00862.","journal-title":"Front Neurosci"},{"issue":"6","key":"1223_CR207","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/bph.15224","volume":"178","author":"M Herrando-Grabulosa","year":"2021","unstructured":"Herrando-Grabulosa M, Gaja-Capdevila N, Vela JM, Navarro X. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis. Br J Pharmacol. 2021;178(6):1336\u201352. https:\/\/doi.org\/10.1111\/bph.15224.","journal-title":"Br J Pharmacol"},{"issue":"s1","key":"1223_CR208","doi-asserted-by":"publisher","first-page":"2454759","DOI":"10.1080\/2994399X.2024.2454759","volume":"1","author":"JM Brimson","year":"2025","unstructured":"Brimson JM. Sigma-1 receptors & disease (S1RaD) 2025. Geriatr Pharmacol. 2025;1(s1):2454759. https:\/\/doi.org\/10.1080\/2994399X.2024.2454759.","journal-title":"Geriatr Pharmacol"},{"key":"1223_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00314","volume":"12","author":"J Jia","year":"2018","unstructured":"Jia J, Cheng J, Wang C, Zhen X. Sigma-1 receptor-modulated neuroinflammation in neurological diseases. Front Cell Neurosci. 2018;12:314. https:\/\/doi.org\/10.3389\/fncel.2018.00314.","journal-title":"Front Cell Neurosci"},{"key":"1223_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2013.00175","author":"D Crott\u00e8s","year":"2013","unstructured":"Crott\u00e8s D, Guizouarn H, Martin P, Borgese F, Soriani O. The sigma-1 receptor: a regulator of cancer cell electrical plasticity? Front Physiol. 2013. https:\/\/doi.org\/10.3389\/fphys.2013.00175.","journal-title":"Front Physiol"},{"issue":"11","key":"1223_CR211","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","volume":"10","author":"Q Yang","year":"2020","unstructured":"Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B. 2020;10(11):2156\u201370. https:\/\/doi.org\/10.1016\/j.apsb.2020.04.004.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"1223_CR212","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/jnc.13002","volume":"132","author":"A Shanmugam","year":"2015","unstructured":"Shanmugam A, Wang J, Markand S, Perry RL, Tawfik A, Zorrilla E, et al. Sigma receptor 1 activation attenuates release of inflammatory cytokines MIP1\u03b3, MIP2, MIP3\u03b1, and IL12 (p40\/p70) by retinal M\u00fcller glial cells. J Neurochem. 2015;132(5):546\u201358. https:\/\/doi.org\/10.1111\/jnc.13002.","journal-title":"J Neurochem"},{"issue":"6","key":"1223_CR213","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1167\/iovs.13-12823","volume":"55","author":"J Zhao","year":"2014","unstructured":"Zhao J, Ha Y, Liou GI, Gonsalvez GB, Smith SB, Bollinger KE. Sigma receptor ligand, (+)-pentazocine, suppresses inflammatory responses of retinal microglia. Investig Ophthalmol Vis Sci. 2014;55(6):3375\u201384. https:\/\/doi.org\/10.1167\/iovs.13-12823.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"1223_CR214","doi-asserted-by":"publisher","first-page":"775","DOI":"10.4103\/1673-5374.232459","volume":"13","author":"J Bruna","year":"2018","unstructured":"Bruna J, Velasco R. Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. Neural Regen Res. 2018;13(5):775\u20138. https:\/\/doi.org\/10.4103\/1673-5374.232459.","journal-title":"Neural Regen Res"},{"issue":"1","key":"1223_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s44324-025-00049-2","volume":"3","author":"F Borbolis","year":"2025","unstructured":"Borbolis F, Ploumi C, Palikaras K. Calcium-mediated regulation of mitophagy: implications in neurodegenerative diseases. NPJ Metab Health Dis. 2025;3(1):4. https:\/\/doi.org\/10.1038\/s44324-025-00049-2.","journal-title":"NPJ Metab Health Dis"},{"key":"1223_CR216","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/cdr.2023.145","volume":"7","author":"N Kumari","year":"2024","unstructured":"Kumari N, Pullaguri N, Rath SN, Bajaj A, Sahu V, Ealla KKR. Dysregulation of calcium homeostasis in cancer and its role in chemoresistance. Cancer Drug Resist. 2024;7:11. https:\/\/doi.org\/10.20517\/cdr.2023.145.","journal-title":"Cancer Drug Resist."},{"issue":"6","key":"1223_CR217","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060741","volume":"17","author":"SK Niazi","year":"2024","unstructured":"Niazi SK, Magoola M, Mariam Z. Innovative therapeutic strategies in Alzheimer\u2019s disease: a synergistic approach to neurodegenerative disorders. Pharmaceuticals. 2024;17(6):741. https:\/\/doi.org\/10.3390\/ph17060741.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1223_CR218","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01607-9","volume":"22","author":"A Doostmohammadi","year":"2024","unstructured":"Doostmohammadi A, Jooya H, Ghorbanian K, Gohari S, Dadashpour M. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Commun Signal. 2024;22(1):228. https:\/\/doi.org\/10.1186\/s12964-024-01607-9.","journal-title":"Cell Commun Signal"},{"key":"1223_CR219","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.freeradbiomed.2015.04.009","volume":"86","author":"J Wang","year":"2015","unstructured":"Wang J, Shanmugam A, Markand S, Zorrilla E, Ganapathy V, Smith SB. Sigma 1 receptor regulates the oxidative stress response in primary retinal M\u00fcller glial cells via NRF2 signaling and system xc\u2212, the Na+-independent glutamate\u2013cystine exchanger. Free Radic Biol Med. 2015;86:25\u201336. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.04.009.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"1223_CR220","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1111\/j.0953-816x.2004.03297.x","volume":"19","author":"M Peeters","year":"2004","unstructured":"Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci. 2004;19(8):2212\u201320. https:\/\/doi.org\/10.1111\/j.0953-816x.2004.03297.x.","journal-title":"Eur J Neurosci"},{"issue":"5","key":"1223_CR221","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7164\/antibiotics.53.467","volume":"53","author":"K Kumagai","year":"2000","unstructured":"Kumagai K, Shono K, Nakayama H, Ohno Y, Saji I. (2R-trans)-2-butyl-5-heptylpyrrolidine as a potent sigma receptor ligand produced by Streptomyces longispororuber. J Antibiot. 2000;53(5):467\u201373. https:\/\/doi.org\/10.7164\/antibiotics.53.467.","journal-title":"J Antibiot"},{"issue":"1\u20132","key":"1223_CR222","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000440864","volume":"16","author":"A Fisher","year":"2016","unstructured":"Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, et al. AF710B, a novel M1\/\u03c31 agonist with therapeutic efficacy in animal models of Alzheimer\u2019s disease. Neurodegener Dis. 2016;16(1\u20132):95\u2013110. https:\/\/doi.org\/10.1159\/000440864.","journal-title":"Neurodegener Dis"},{"issue":"2","key":"1223_CR223","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.expneurol.2007.06.013","volume":"207","author":"LL Werling","year":"2007","unstructured":"Werling LL, Keller A, Frank JG, Nuwayhid SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207(2):248\u201357. https:\/\/doi.org\/10.1016\/j.expneurol.2007.06.013.","journal-title":"Exp Neurol"},{"issue":"8","key":"1223_CR224","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0269881110379286","volume":"25","author":"V Villard","year":"2011","unstructured":"Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma1 (\u03c31) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011;25(8):1101\u201317. https:\/\/doi.org\/10.1177\/0269881110379286.","journal-title":"J Psychopharmacol"},{"key":"1223_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2021.107129","volume":"113","author":"DA Dalwadi","year":"2022","unstructured":"Dalwadi DA, Kim S, Schetz J, Schreihofer DA, Kim S. Brain-derived neurotrophic factor for high-throughput evaluation of selective sigma-1 receptor ligands. J Pharmacol Toxicol Methods. 2022;113:107129. https:\/\/doi.org\/10.1016\/j.vascn.2021.107129.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"10","key":"1223_CR226","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/0269881113497614","volume":"27","author":"RM Ring","year":"2013","unstructured":"Ring RM, Regan CM. Captodiamine, a putative antidepressant, enhances hypothalamic BDNF expression in vivo by synergistic 5-HT2c receptor antagonism and sigma-1 receptor agonism. J Psychopharmacol. 2013;27(10):930\u20139. https:\/\/doi.org\/10.1177\/0269881113497614.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1223_CR227","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","volume":"307","author":"N Narita","year":"1996","unstructured":"Narita N, Hashimoto K, Tomitaka S-i, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of \u03c3 receptors in rat brain. Eur J Pharmacol. 1996;307(1):117\u20139. https:\/\/doi.org\/10.1016\/0014-2999(96)00254-3.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1223_CR228","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0022-3565(25)10150-X","volume":"264","author":"MC Ritz","year":"1993","unstructured":"Ritz MC, George FR. Cocaine-induced seizures and lethality appear to be associated with distinct central nervous system binding sites. J Pharmacol Exp Ther. 1993;264(3):1333\u201343.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1223_CR229","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/syn.21717","volume":"68","author":"JR Lever","year":"2014","unstructured":"Lever JR, Miller DK, Green CL, Fergason-cantrell EA, Watkinson LD, Carmack TL, et al. A selective sigma-2 receptor ligand antagonizes cocaine-induced hyperlocomotion in mice. Synapse. 2014;68(2):73\u201384. https:\/\/doi.org\/10.1002\/syn.21717.","journal-title":"Synapse"},{"issue":"6","key":"1223_CR230","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/hipo.20281","volume":"17","author":"PTH Nguyen","year":"2007","unstructured":"Nguyen PTH, Kimura T, Ho SA, Tran AH, Ono T, Nishijo H. Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-\u03b2 peptide (1\u201340) in rats. Hippocampus. 2007;17(6):443\u201355. https:\/\/doi.org\/10.1002\/hipo.20281.","journal-title":"Hippocampus"},{"issue":"1","key":"1223_CR231","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jphs.2014.11.010","volume":"127","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci. 2015;127(1):6\u20139. https:\/\/doi.org\/10.1016\/j.jphs.2014.11.010.","journal-title":"J Pharmacol Sci"},{"key":"1223_CR232","doi-asserted-by":"publisher","DOI":"10.1002\/9781118185537","volume-title":"Therapeutic targets: modulation, inhibition, and activation","author":"LM Botana","year":"2012","unstructured":"Botana LM, Loza M. Therapeutic targets: modulation, inhibition, and activation. New York: Wiley; 2012."},{"issue":"7","key":"1223_CR233","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/s0028-3908(03)00253-3","volume":"45","author":"D Moison","year":"2003","unstructured":"Moison D, De Deurwaerd\u00e8re P, Cagnotto A, Marrazzo A, Prezzavento O, Ronsisvalle G, et al. Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo. Neuropharmacology. 2003;45(7):945\u201353. https:\/\/doi.org\/10.1016\/s0028-3908(03)00253-3.","journal-title":"Neuropharmacology"},{"key":"1223_CR234","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115455","author":"MV Voronin","year":"2021","unstructured":"Voronin MV, Vakhitova YV, Tsypysheva IP, Tsypyshev DO, Rybina IV, Kurbanov RD, et al. Involvement of chaperone sigma1R in the anxiolytic effect of fabomotizole. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115455.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"1223_CR235","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1016\/j.bmcl.2017.04.088","volume":"27","author":"E Sguazzini","year":"2017","unstructured":"Sguazzini E, Schmidt HR, Iyer KA, Kruse AC, Dukat M. Reevaluation of fenpropimorph as a \u03c3 receptor ligand: structure-affinity relationship studies at human \u03c31 receptors. Bioorg Med Chem Lett. 2017;27(13):2912\u20139. https:\/\/doi.org\/10.1016\/j.bmcl.2017.04.088.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"1223_CR236","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuropharm.2005.04.016","volume":"49","author":"EC Nguyen","year":"2005","unstructured":"Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR. Involvement of sigma (\u03c3) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology. 2005;49(5):638\u201345. https:\/\/doi.org\/10.1016\/j.neuropharm.2005.04.016.","journal-title":"Neuropharmacology"},{"issue":"5916","key":"1223_CR237","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.1166127","volume":"323","author":"D Fontanilla","year":"2009","unstructured":"Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323(5916):934\u20137. https:\/\/doi.org\/10.1126\/science.1166127.","journal-title":"Science"},{"issue":"1","key":"1223_CR238","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0026-895X(25)00612-1","volume":"36","author":"MA Sills","year":"1989","unstructured":"Sills MA, Loo PS. Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and l-glutamate. Mol Pharmacol. 1989;36(1):160\u20135.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"1223_CR239","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0028-3908(96)00161-x","volume":"36","author":"HC Akunne","year":"1997","unstructured":"Akunne HC, Whetzel SZ, Wiley JN, Corbin AE, Ninteman FW, Tecle H, et al. The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology. 1997;36(1):51\u201362. https:\/\/doi.org\/10.1016\/s0028-3908(96)00161-x.","journal-title":"Neuropharmacology"},{"issue":"2","key":"1223_CR240","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/bf00711241","volume":"8","author":"JM Musacchio","year":"1988","unstructured":"Musacchio JM, Klein M. Dextromethorphan binding sites in the guinea pig brain. Cell Mol Neurobiol. 1988;8(2):149\u201356. https:\/\/doi.org\/10.1007\/bf00711241.","journal-title":"Cell Mol Neurobiol"},{"key":"1223_CR241","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.neuropharm.2018.10.028","volume":"144","author":"DM Riddy","year":"2019","unstructured":"Riddy DM, Cook AE, Shackleford DM, Pierce TL, Mocaer E, Mannoury la Cour C, et al. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H(3) receptor antagonists. Neuropharmacology. 2019;144:244\u201355. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.10.028.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1223_CR242","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1471-4159.2009.06000.x","volume":"109","author":"V Antonini","year":"2009","unstructured":"Antonini V, Prezzavento O, Coradazzi M, Marrazzo A, Ronsisvalle S, Arena E, et al. Anti-amnesic properties of (+\/\u2212)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. J Neurochem. 2009;109(3):744\u201354. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06000.x.","journal-title":"J Neurochem"},{"issue":"3","key":"1223_CR243","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.biopsych.2010.07.026","volume":"69","author":"L Garc\u00e9s-Ram\u00edrez","year":"2011","unstructured":"Garc\u00e9s-Ram\u00edrez L, Green JL, Hiranita T, Kopajtic TA, Mereu M, Thomas AM, et al. Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry. 2011;69(3):208\u201317. https:\/\/doi.org\/10.1016\/j.biopsych.2010.07.026.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1223_CR244","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0022-3565(25)20283-X","volume":"259","author":"T-P Su","year":"1991","unstructured":"Su T-P, Wu XZ, Cone EJ, Shukla K, Gund TM, Dodge AL, et al. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. J Pharmacol Exp Ther. 1991;259(2):543\u201350.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1223_CR245","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/mp.2012.3","volume":"18","author":"K Sahlholm","year":"2013","unstructured":"Sahlholm K, \u00c5rhem P, Fuxe K, Marcellino D. The dopamine stabilizers ACR16 and (\u2212)-OSU6162 display nanomolar affinities at the \u03c3-1 receptor. Mol Psychiatry. 2013;18(1):12\u20134. https:\/\/doi.org\/10.1038\/mp.2012.3.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"1223_CR246","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mds.27565","volume":"34","author":"TH Johnston","year":"2019","unstructured":"Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, et al. Pridopidine, a clinic-ready compound, reduces 3, 4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov Disord. 2019;34(5):708\u201316. https:\/\/doi.org\/10.1002\/mds.27565.","journal-title":"Mov Disord"},{"issue":"6","key":"1223_CR247","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/syn.20253","volume":"59","author":"JR Lever","year":"2006","unstructured":"Lever JR, Gustafson JL, Xu R, Allmon RL, Lever SZ. \u03c31 and \u03c32 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse. 2006;59(6):350\u20138. https:\/\/doi.org\/10.1002\/syn.20253.","journal-title":"Synapse"},{"issue":"11","key":"1223_CR248","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.1021\/acs.jmedchem.4c00288","volume":"67","author":"U Christmann","year":"2024","unstructured":"Christmann U, Garriga L, Llorente AV, D\u00edaz JL, Pascual R, Bordas M, et al. WLB-87848, a selective \u03c3(1) receptor agonist, with an unusually positioned NH group as positive ionizable moiety and showing neuroprotective activity. J Med Chem. 2024;67(11):9150\u201364. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00288.","journal-title":"J Med Chem"},{"issue":"2","key":"1223_CR249","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ptr.8068","volume":"38","author":"L Crouzier","year":"2024","unstructured":"Crouzier L, Meunier J, Carles A, Morilleau A, Vrigneau C, Schmitt M, et al. Convolamine, a tropane alkaloid extracted from Convolvulus plauricalis, is a potent sigma-1 receptor-positive modulator with cognitive and neuroprotective properties. Phytother Res. 2024;38(2):694\u2013712. https:\/\/doi.org\/10.1002\/ptr.8068.","journal-title":"Phytother Res"},{"issue":"3","key":"1223_CR250","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bph.12506","volume":"171","author":"L Zvejniece","year":"2014","unstructured":"Zvejniece L, Vavers E, Svalbe B, Vilskersts R, Domracheva I, Vorona M, et al. The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors. Br J Pharmacol. 2014;171(3):761\u201371. https:\/\/doi.org\/10.1111\/bph.12506.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1223_CR251","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1016\/j.bmc.2013.03.016","volume":"21","author":"G Veinberg","year":"2013","unstructured":"Veinberg G, Vorona M, Zvejniece L, Vilskersts R, Vavers E, Liepinsh E, et al. Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor. Bioorg Med Chem. 2013;21(10):2764\u201371. https:\/\/doi.org\/10.1016\/j.bmc.2013.03.016.","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"1223_CR252","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1124\/mol.112.083840","volume":"83","author":"L Guo","year":"2013","unstructured":"Guo L, Zhao J, Jin G, Zhao B, Wang G, Zhang A, et al. SKF83959 is a potent allosteric modulator of sigma-1 receptor. Mol Pharmacol. 2013;83(3):577\u201386. https:\/\/doi.org\/10.1124\/mol.112.083840.","journal-title":"Mol Pharmacol"},{"issue":"16","key":"1223_CR253","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1111\/bph.13195","volume":"172","author":"L Guo","year":"2015","unstructured":"Guo L, Chen Y, Zhao R, Wang G, Friedman E, Zhang A, et al. Allosteric modulation of sigma-1 receptors elicits anti-seizure activities. Br J Pharmacol. 2015;172(16):4052\u201365. https:\/\/doi.org\/10.1111\/bph.13195.","journal-title":"Br J Pharmacol"},{"key":"1223_CR254","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112144","volume":"191","author":"J Xiong","year":"2020","unstructured":"Xiong J, Jin J, Gao L, Hao C, Liu X, Liu B-F, et al. Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain. Eur J Med Chem. 2020;191:112144. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112144.","journal-title":"Eur J Med Chem"},{"issue":"23","key":"1223_CR255","doi-asserted-by":"publisher","first-page":"16257","DOI":"10.1021\/acs.jmedchem.3c01637","volume":"66","author":"Z Miao","year":"2023","unstructured":"Miao Z, Zhong Y, Gan Y, Fu K, Liu W, Cao Z, et al. A novel bifunctional \u03bcOR agonist and \u03c3(1)R antagonist with potent analgesic responses and reduced adverse effects. J Med Chem. 2023;66(23):16257\u201375. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01637.","journal-title":"J Med Chem"},{"key":"1223_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117037","volume":"281","author":"G Cosentino","year":"2025","unstructured":"Cosentino G, Dichiara M, Ambrosio FA, Leotta CG, Costa G, Procopio F, et al. Development of selective sigma-1 receptor ligands with antiallodynic activity: a focus on piperidine and piperazine scaffolds. Eur J Med Chem. 2025;281:117037. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117037.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"1223_CR257","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4196\/kjpp.2009.13.6.425","volume":"13","author":"YB Kwon","year":"2009","unstructured":"Kwon YB, Jeong YC, Kwon JK, Son JS, Kim KW. The antinociceptive effect of sigma-1 receptor antagonist, BD1047, in a capsaicin induced headache model in rats. Korean J Physiol Pharmacol. 2009;13(6):425\u20139. https:\/\/doi.org\/10.4196\/kjpp.2009.13.6.425.","journal-title":"Korean J Physiol Pharmacol"},{"issue":"2","key":"1223_CR258","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0014-2999(01)00968-2","volume":"419","author":"RR Matsumoto","year":"2001","unstructured":"Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting \u03c31 receptors produce anti-cocaine effects in mice. Eur J Pharmacol. 2001;419(2):163\u201374. https:\/\/doi.org\/10.1016\/S0014-2999(01)00968-2.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1223_CR259","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00213-009-1505-8","volume":"204","author":"MA Paquette","year":"2009","unstructured":"Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology. 2009;204(4):743\u201354. https:\/\/doi.org\/10.1007\/s00213-009-1505-8.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1223_CR260","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0014-2999(00)00430-1","volume":"401","author":"RR Matsumoto","year":"2000","unstructured":"Matsumoto RR, Pouw B. Correlation between neuroleptic binding to \u03c31 and \u03c32 receptors and acute dystonic reactions. Eur J Pharmacol. 2000;401(2):155\u201360. https:\/\/doi.org\/10.1016\/s0014-2999(00)00430-1.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1223_CR261","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1248\/bpb.b19-00542","volume":"43","author":"S Yeste","year":"2020","unstructured":"Yeste S, Reinoso RF, Ayet E, Pretel MJ, Balada A, Serafini MT. Preliminary in vitro assessment of the potential of EST64454, a sigma-1 receptor antagonist, for pharmacokinetic drug-drug interactions. Biol Pharm Bull. 2020;43(1):68\u201376. https:\/\/doi.org\/10.1248\/bpb.b19-00542.","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"1223_CR262","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1535-7163.Mct-05-0402","volume":"5","author":"A Azzariti","year":"2006","unstructured":"Azzariti A, Colabufo NA, Berardi F, Porcelli L, Niso M, Simone GM, et al. Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol Cancer Ther. 2006;5(7):1807\u201316. https:\/\/doi.org\/10.1158\/1535-7163.Mct-05-0402.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1223_CR263","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.ebiom.2015.10.017","volume":"2","author":"UB Chu","year":"2015","unstructured":"Chu UB, Mavlyutov TA, Chu M-L, Yang H, Schulman A, Mesangeau C, et al. The sigma-2 receptor and progesterone receptor membrane component 1 are different binding sites derived from independent genes. EBioMedicine. 2015;2(11):1806\u201313. https:\/\/doi.org\/10.1016\/j.ebiom.2015.10.017.","journal-title":"EBioMedicine"},{"issue":"8","key":"1223_CR264","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1021\/acsptsci.4c00186","volume":"7","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhang AH, Wei L, Welsh WJ. Preclinical evaluation of sigma 1 receptor antagonists as a novel treatment for painful diabetic neuropathy. ACS Pharmacol Transl Sci. 2024;7(8):2358\u201368. https:\/\/doi.org\/10.1021\/acsptsci.4c00186.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"24","key":"1223_CR265","doi-asserted-by":"publisher","first-page":"10404","DOI":"10.1021\/jm501207r","volume":"57","author":"Y Lan","year":"2014","unstructured":"Lan Y, Chen Y, Cao X, Zhang J, Wang J, Xu X, et al. Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain. J Med Chem. 2014;57(24):10404\u201323. https:\/\/doi.org\/10.1021\/jm501207r.","journal-title":"J Med Chem"},{"issue":"1","key":"1223_CR266","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2006.10.020","volume":"555","author":"X Liu","year":"2007","unstructured":"Liu X, Banister SD, Christie MJ, Banati R, Meikle S, Coster MJ, et al. Trishomocubanes: novel sigma ligands modulate cocaine-induced behavioural effects. Eur J Pharmacol. 2007;555(1):37\u201342. https:\/\/doi.org\/10.1016\/j.ejphar.2006.10.020.","journal-title":"Eur J Pharmacol"},{"key":"1223_CR267","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107537","volume":"150","author":"JM Entrena","year":"2024","unstructured":"Entrena JM, Artacho-Cord\u00f3n A, Ravez S, Liberelle M, Melnyk P, Toledano-Pinedo M, et al. The proof of concept of 2-{3-[N-(1-benzylpiperidin-4-yl)propyl]amino}-6-[N-methyl-N-(prop-2-yn-1-yl)amino]-4-phenylpyridine-3,5-dicarbonitrile for the therapy of neuropathic pain. Bioorg Chem. 2024;150:107537. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107537.","journal-title":"Bioorg Chem"},{"key":"1223_CR268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2007.08.068","volume":"1181","author":"JA Schetz","year":"2007","unstructured":"Schetz JA, Perez E, Liu R, Chen S, Lee I, Simpkins JW. A prototypical sigma-1 receptor antagonist protects against brain ischemia. Brain Res. 2007;1181:1\u20139. https:\/\/doi.org\/10.1016\/j.brainres.2007.08.068.","journal-title":"Brain Res"},{"issue":"6","key":"1223_CR269","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0006-2952(94)00541-S","volume":"49","author":"SMN Efange","year":"1995","unstructured":"Efange SMN, Mach RH, Smith CR, Khare AB, Foulon C, Akella SK, et al. Vesamicol analogues as sigma ligands: molecular determinants of selectivity at the vesamicol receptor. Biochem Pharmacol. 1995;49(6):791\u20137. https:\/\/doi.org\/10.1016\/0006-2952(94)00541-S.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"1223_CR270","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.1021\/acs.jmedchem.4c02549","volume":"68","author":"A Carrel","year":"2025","unstructured":"Carrel A, Yiannakas A, Roukens JJ, Reynoso-Moreno I, Orsi M, Thakkar A, et al. Exploring simple drug scaffolds from the generated database chemical space reveals a chiral bicyclic azepane with potent neuropharmacology. J Med Chem. 2025;68(9):9176\u2013201. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02549.","journal-title":"J Med Chem"},{"issue":"2","key":"1223_CR271","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0922-4106(94)90102-3","volume":"266","author":"A Cagnotto","year":"1994","unstructured":"Cagnotto A, Bastone A, Mennini T. [3H](+)-Pentazocine binding to rat brain \u03c31 receptors. Eur J Pharmacol Mol Pharmacol. 1994;266(2):131\u20138. https:\/\/doi.org\/10.1016\/0922-4106(94)90102-3.","journal-title":"Eur J Pharmacol Mol Pharmacol"},{"issue":"1","key":"1223_CR272","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acs.jcim.8b00521","volume":"59","author":"Y Peng","year":"2019","unstructured":"Peng Y, Dong H, Welsh WJ. Comprehensive 3d-QSAR model predicts binding affinity of structurally diverse sigma 1 receptor ligands. J Chem Inf Model. 2019;59(1):486\u201397. https:\/\/doi.org\/10.1021\/acs.jcim.8b00521.","journal-title":"J Chem Inf Model"},{"issue":"2","key":"1223_CR273","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1124\/jpet.115.224105","volume":"354","author":"H Nicholson","year":"2015","unstructured":"Nicholson H, Comeau A, Mesangeau C, McCurdy CR, Bowen WD. Characterization of CM572, a selective irreversible partial agonist of the sigma-2 receptor with antitumor activity. J Pharmacol Exp Ther. 2015;354(2):203\u201312. https:\/\/doi.org\/10.1124\/jpet.115.224105.","journal-title":"J Pharmacol Exp Ther"},{"issue":"23","key":"1223_CR274","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.1016\/j.bmc.2012.09.044","volume":"20","author":"KS Marriott","year":"2012","unstructured":"Marriott KS, Morrison AZ, Moore M, Olubajo O, Stewart LE. Synthesis of N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamides as new selective ligands for sigma receptors. Bioorg Med Chem. 2012;20(23):6856\u201361. https:\/\/doi.org\/10.1016\/j.bmc.2012.09.044.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"1223_CR275","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0014-2999(94)90286-0","volume":"271","author":"RL Hudkins","year":"1994","unstructured":"Hudkins RL, Mailman RB, DeHaven-Hudkins DL. RLH-033, a novel, potent and selective ligand for the sigma 1 recognition site. Eur J Pharmacol. 1994;271(1):235\u20136. https:\/\/doi.org\/10.1016\/0014-2999(94)90286-0.","journal-title":"Eur J Pharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01223-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:05:41Z","timestamp":1762884341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01223-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":275,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01223-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.P., S.T.S., S.B., and J.M.B. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: J.M.B. and S.B. Drafting manuscript: A.P., S.B., S.T.S., and J.M.B. Editing manuscript: J.M.B., S.B., and S.T.S. Preparation of figures: J.M.B. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}